Method and compositions for synthesizing improved silk fibers
Patent Information
- Application Number
- JP2024134795
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2013-09-17
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for producing recombinant silk fibers are not commercially scalable and do not achieve the small diameters necessary for microfiber characteristics, lacking the flexibility, strength, and other properties desirable for microfiber fabrics.
Development of proteinaceous block copolymers with specific amino acid compositions and domains, assembled into fibers using engineered microorganisms like Pichia pastoris and Bacillus subtilis, enabling high-rate secretion and production of fibers with diameters as small as 4-12.7 μm, which can be processed into microfibers.
The method produces fibers with mechanical properties suitable for microfiber applications, including high strength, flexibility, and durability, replicating the properties of natural silk fibers at a commercially viable scale.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 61 / 878,858, filed Sep. 17, 2013, the entire teachings of which are incorporated herein by reference for all purposes.
[0002] Sequence Listing This application contains a Sequence Listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. Created on September 16, 2014, the ASCII copy is named 27321PCT_CRF_SequenceListing.txt and is 4,189,730 bytes in size.
[0003] FIELD OF THEINVENTION The present disclosure relates to methods and compositions relating to synthetic block copolymer proteins, expression constructs for their secretion, recombinant microorganisms for their production, and synthetic fibers comprising these proteins that recapitulate many of the properties of natural silk. [Background technology]
[0004] 2. Background of the Invention Spider silk polypeptides are large (>150 kDa, >1000 amino acids) polypeptides that can be broken down into three domains: the N-terminal non-repetitive domain (NTD), the repeat domain (REP), and the C-terminal non-repetitive domain (CTD). The NTD and CTD are relatively small (~150 and ~100 amino acids, respectively), well studied, and are thought to confer aqueous stability, pH sensitivity, and molecular order upon aggregation to the polypeptide. The NTD also has a strongly predicted secretion tag, which is often removed during heterologous expression. The repeat regions constitute about 90% of the native polypeptide and fold into crystalline and amorphous regions that confer strength and flexibility, respectively, to the silk fiber.
[0005] Silk polypeptides are derived from a variety of sources, including bees, moths, spiders, mites, and other arthropods. Some organisms make multiple silk fibers with unique sequences, structural elements, and mechanical properties. For example, the long-toed orb-weaver spider has six unique types of glands that produce different silk polypeptide sequences that are polymerized into fibers tailored to suit the environment or life cycle stage. The fibers are named for the gland from which they occur, and the polypeptides are designated by an abbreviation for the gland (e.g., "Ma") and "Sp" for spidroin (short for spider fibroin). In the orb weaver, these types include Major Ampullate (MaSp, also called dragline silk), Minor Ampullate (MiSp), Flagelliform (Flag), Aciniform (AcSp), Tubuliform (TuSp), and Pyriform (PySp). This combination of polypeptide sequences across fiber types, domains, and variations among different genera and species of organisms results in a myriad of potential properties that can be exploited by commercial production of recombinant fibers. To date, the majority of recombinant silk research has focused on Major Ampullate spidroins (MaSp).
[0006] Currently, recombinant silk fibers are not commercially available and, with a handful of exceptions, have not been produced in microorganisms other than Escherichia coli and other Gram-negative prokaryotes. Recombinant silk produced to date has consisted mostly of polymerized short silk sequence motifs or fragments of native repeat domains, sometimes combined with NTDs and / or CTDs. This has resulted in small-scale production of recombinant silk polypeptides (milligrams at laboratory scale, kilograms at bioprocessing scale) produced using intracellular expression and purification by chromatography or bulk precipitation. These methods do not provide viable commercial scalability that can compete with existing technical and textile fiber prices. Additional production hosts that have been used to produce silk polypeptides include transgenic goats, transgenic silkworms, and plants. These hosts have not yet enabled commercial-scale production of silk, likely due to slow engineering cycles and poor scalability.
[0007] Microfibers are a classification of fibers with a fineness of less than 1 decitex (dtex), approximately 10 μm in diameter. HK, Kaynak and O. Babaarslan, Woven Fabrics, Croatia: InTech, 2012. The small diameter of microfibers gives microfiber yarns and textiles various properties and characteristics that are desirable to consumers. Microfibers are inherently more flexible (bending is inversely proportional to fiber diameter) and therefore have a soft feel, low stiffness and high drapeability. Microfibers can also be spun into yarns with high fiber density (more fibers per yarn cross-sectional area), giving microfiber yarns higher strength compared to other yarns of similar dimensions. Microfibers also contribute to individual stress relaxation within the yarn, resulting in wrinkle-free textiles. Furthermore, microfibers have high compression efficiency within the yarn, which improves textile waterproof and windproof properties while maintaining breathability compared to other waterproof and windproof technologies (e.g., polyvinyl coatings). The high density of fibers in microfiber fabrics creates microchannel structures between the fibers, which promotes the capillary effect and imparts wicking and quick-drying characteristics. The high surface area to volume of microfiber yarns allows them to be dyed brighter and more vividly, and printed textiles have clearer and sharper pattern retention as well. Currently, recombinant silk fibers do not have sufficiently small fineness to produce silk with microfiber-type characteristics. U.S. Patent Application Publication No. 2014 / 0058066 (Patent Document 1) discloses fiber diameters of approximately 5 to 100 μm, but does not actually disclose any examples of fibers with diameters as small as 5 μm.
[0008] What is needed, therefore, are improved methods and compositions for recombinant block copolymer proteins, expression constructs for their secretion at high rates, microorganisms that express these proteins, and synthetic fibers made from these proteins that recapitulate many of the properties of silk fibers, e.g., fibers with small diameters useful for microfiber textiles. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] US Patent Application Publication No. 2014 / 0058066 [Non-patent literature]
[0010] [Non-Patent Document 1] HK, Kaynak and O. Babaarslan, Woven Fabrics, Croatia: InTech, 2012 Summary of the Invention
[0011] The present invention provides compositions of proteinaceous block copolymers capable of assembling into fibers, and methods of making the same. The proteinaceous block copolymers include quasi-repeat domains, and the copolymers are capable of assembling into fibers. In some embodiments, the copolymers include an alanine composition of 12-40% of the amino acid sequence of the copolymer, a glycine composition of 25-50% of the amino acid sequence of the copolymer, a proline composition of 9-20% of the amino acid sequence of the copolymer, a β-turn composition of 15-37% of the amino acid sequence of the copolymer, a GPG amino acid motif content of 18-55% of the amino acid sequence of the copolymer, and a polyalanine amino acid motif content of 9-35% of the total amino acids of the copolymer.
[0012] In some embodiments, the copolymer also comprises an N-terminal non-repeat domain between 75 and 350 amino acids in length, and a C-terminal non-repeat domain between 75 and 350 amino acids in length. In some embodiments, the pseudo-repeat domain is between 500 and 5000, between 119 and 1575, or between 900 and 950 amino acids in length. In other embodiments, the mass of the copolymer is between 40 and 400, between 12.2 and 132, or between 70 and 100 kDa. In some embodiments, the alanine composition is between 16 and 31% or between 15 and 20% of the amino acid sequence of the copolymer. In other embodiments, the glycine composition is between 29 and 43% or between 38 and 43% of the amino acid sequence of the copolymer. In some embodiments, the proline composition is between 11 and 16% or between 13 and 15% of the amino acid sequence of the copolymer. In other embodiments, the β-turn composition is between 18 and 33% or between 25 and 30% of the amino acid sequence of the copolymer. In some embodiments, the GPG amino acid motif content is between 22-47% or between 30-45% of the amino acid sequence of the copolymer. In other embodiments, the polyalanine amino acid motif content is between 12-29% of the amino acid sequence of the copolymer. In some embodiments, the copolymer comprises a sequence from Table 13a, SEQ ID NO: 1396, or SEQ ID NO: 1374. In other embodiments, the copolymer consists of SEQ ID NO: 1398 or SEQ ID NO: 2770.
[0013] In some embodiments, the engineered microorganism comprises a heterologous nucleic acid molecule encoding a secretion signal and a coding sequence, the coding sequence encoding the copolymer described above, and the secretion signal allows for secretion of the copolymer from the microorganism. In further embodiments, the engineered microorganism is Pichia pastoris or Bacillus subtilis. In other embodiments, the cell culture comprises a culture medium and the engineered microorganism. In other embodiments, a method for producing a secreted block copolymer comprises obtaining a cell culture medium and maintaining the cell culture medium under conditions that cause the engineered microorganism to secrete the copolymer at a rate of at least 2-20 mg silk / g DCW / hr. In further embodiments, the copolymer is secreted at a rate of at least 20 mg silk / g DCW / hr. In still other embodiments, the cell culture medium comprises the secreted copolymer described above.
[0014] In other embodiments, the invention includes a method for producing fibers, comprising obtaining a cell culture medium as described above, isolating the secreted protein, and processing the protein into a spinning solution and producing fibers from the spinning solution. In some embodiments, the fibers comprise the secreted copolymer as described above. In some embodiments, the fibers have a yield stress of 24-172 or 150-172 MPa. In other embodiments, the fibers have a maximum stress of 54-310 or 150-310 MPa. In some embodiments, the fibers have a breaking strain of 2-200% or 180-200%. In other embodiments, the fibers have a diameter of 4.48-12.7 or 4-5 μm. In some embodiments, the fibers have an initial modulus of 1617-5820 or 5500-5820 MPa. In other embodiments, the fibers have a tensile modulus of at least 0.5, 3.1, or 59.2 MJ / m 3 In yet another embodiment, the fiber has a fineness of 0.2 to 0.6 denier.
[0015] [The present invention 1001] A proteinaceous block copolymer comprising quasi-repeat domains, capable of assembling into fibers; and an alanine composition of 12 to 40% of the amino acid sequence of the copolymer; a glycine composition of 25 to 50% of the amino acid sequence of the copolymer; a proline composition of 9 to 20% of the amino acid sequence of the copolymer; a β-turn composition of 15 to 37% of the amino acid sequence of the copolymer; a GPG amino acid motif content of 18 to 55% of the amino acid sequence of the copolymer; and A polyalanine amino acid motif content of 9 to 35% of the total amino acids of the copolymer A proteinaceous block copolymer comprising: [The present invention 1002] The copolymer of the present invention 1001, further comprising an N-terminal non-repetitive domain of 75 to 350 amino acids in length and a C-terminal non-repetitive domain of 75 to 350 amino acids in length. [The present invention 1003] The copolymer of the present invention, wherein the quasi-repeat domain is 500 to 5000 amino acids in length. [The present invention 1004] The copolymer of the present invention, wherein the quasi-repeat domain is 119 to 1575 amino acids in length. [The present invention 1005] The copolymer of the present invention, wherein the quasi-repeat domain is 900-950 amino acids in length. [The present invention 1006] The copolymer of the present invention, wherein the mass of the copolymer is 40 to 400 kDa. [The present invention 1007] The copolymer of the present invention, wherein the mass of the copolymer is 12.2 to 132 kDa. [The present invention 1008] The copolymer of the present invention, wherein the mass of the copolymer is 70 to 100 kDa. [The present invention 1009] The copolymer of the present invention, wherein the alanine composition is 16-31% of the amino acid sequence of said copolymer. [The present invention 1010] The copolymer of the present invention, wherein the alanine composition is 15-20% of the amino acid sequence of said copolymer. [The present invention 1011] The copolymer of the present invention, wherein the glycine composition is 29-43% of the amino acid sequence of said copolymer. [The present invention 1012] The copolymer of the present invention, wherein the glycine composition is 38-43% of the amino acid sequence of said copolymer. [The present invention 1013] The copolymer of the present invention, wherein the proline composition is 11-16% of the amino acid sequence of said copolymer. [The present invention 1014] The copolymer of the present invention, wherein the proline composition is 13-15% of the amino acid sequence of said copolymer. [The present invention 1015] The copolymer of the present invention, wherein the β-turn composition is 18-33% of the amino acid sequence of said copolymer. [The present invention 1016] The copolymer of the present invention, wherein the β-turn composition is 25-30% of the amino acid sequence of said copolymer. [The present invention 1017] The copolymer of the present invention, wherein the GPG amino acid motif content is 22-47% of the amino acid sequence of said copolymer. [The present invention 1018] The copolymer of the present invention, wherein the GPG amino acid motif content is 30-45% of the amino acid sequence of said copolymer. [The present invention 1019] The copolymer of the present invention, wherein the polyalanine amino acid motif content is 12-29% of the amino acid sequence of said copolymer. [The present invention 1020] Copolymers of the present invention 1001 comprising sequences from Table 13a. [The present invention 1021] The copolymer of the present invention, comprising SEQ ID NO: 1396. [The present invention 1022] The copolymer of the present invention, comprising SEQ ID NO: 1398. [The present invention 1023] The copolymer of the present invention, comprising SEQ ID NO: 1374. [The present invention 1024] The copolymer of the present invention 1001, consisting of SEQ ID NO: 2770. [The present invention 1025] An engineered microorganism comprising a heterologous nucleic acid molecule encoding a secretion signal and a coding sequence, wherein the coding sequence encodes a copolymer of the present invention and the secretion signal allows for secretion of the copolymer from the microorganism. [The present invention 1026] The modified microorganism of the present invention, wherein the modified microorganism is Pichia pastoris. [The present invention 1027] The modified microorganism of the present invention, wherein the modified microorganism is Bacillus subtilis. [The present invention 1028] A cell culture comprising a culture medium and a modified microorganism of the present invention. [The present invention 1029] a) obtaining a cell culture medium of the present invention; and b) maintaining the cell culture medium under conditions that allow the modified microorganism to secrete the copolymer at a rate of at least 2-20 mg silk / g DCW / hr. A method for producing a secreted block copolymer comprising: [The present invention 1030] The method of claim 1029, wherein the copolymer is secreted at a rate of at least 20 mg silk / g DCW / hr. [The present invention 1031] A cell culture medium comprising a secreted copolymer of the present invention. [The present invention 1032] a) obtaining a cell culture medium of the present invention; b) isolating the secreted protein, and c) processing the protein into a spinning solution and producing fibers from the spinning solution; A method for producing a fiber comprising: [The present invention 1033] A fiber comprising the secretory copolymer of the present invention. [The present invention 1034] The fiber of the present invention 1033 having a yield stress of 24 to 172 MPa. [The present invention 1035] The fiber of the present invention 1033 having a yield stress of 150 to 172 MPa. [The present invention 1036] The fiber of the present invention 1033 having a maximum stress of 54 to 310 MPa. [The present invention 1037] The fiber of the present invention 1033 having a maximum stress of 150 to 310 MPa. [The present invention 1038] The fiber of the present invention 1033 having a breaking strain of 2 to 200%. [The present invention 1039] The fiber of the present invention 1033 has a breaking strain of 180 to 200%. [The present invention 1040] The fiber of the present invention 1033 having a diameter of 4.48 to 12.7 μm. [The present invention 1041] The fiber of the present invention 1033 having a diameter of 4 to 5 μm. [The present invention 1042] The fiber of the present invention 1033 has an initial modulus of 1617 to 5820 MPa. [The present invention 1043] The fiber of the present invention 1033 has an initial modulus of 5500 to 5820 MPa. [The present invention 1044] At least 0.5 MJ / m 3 The fiber of the present invention having a tenacity value of 1033. [The present invention 1045] At least 3.1 MJ / m 3 The fiber of the present invention having a tenacity value of 1033. [The present invention 1046] At least 59.2 MJ / m 3 The fiber of the present invention having a tenacity value of 1033. [The present invention 1047] The fiber of the present invention 1033 has a fineness of 0.2 to 0.6 denier. These and other aspects of the present invention are now further described in the figures, specification, examples and claims. [Brief description of the drawings]
[0016] [Figure 1] FIG. 1 shows the hierarchical structure of silk polypeptide sequences, including block copolymer structures of natural silk polypeptides. FIG. 1 discloses "AAAAAA" as SEQ ID NO: 2838. [Diagram 2] 1 shows a screening process for silk polypeptide domains and their DNA encoding, according to some embodiments of the present invention. [Diagram 3] FIG. 1 shows how silk repeat sequences and terminal domains that pass preliminary screening are assembled to make functional block copolymers that can be purified and made into fibers, in accordance with an embodiment of the present invention. [Figure 4] Representative Western blots of expressed silk repeat and terminal domain sequences are shown. [Diagram 5] Representative Western blots of expressed silk repeat and terminal domain sequences are shown. [Figure 6] 1 shows the assembly of a block copolymer 18B silk polynucleotide from repeat sequences R1, R2, in accordance with an embodiment of the present invention. [Figure 7] 1 shows an assembly vector used to assemble silk polynucleotide segments according to an embodiment of the present invention. [Figure 8] FIG. 8 shows the ligation of two sequences to form part of a silk polynucleotide sequence according to an embodiment of the present invention. FIG. 8 discloses, in order of appearance, SEQ ID NOs: 2839-2842 and 2841-2843, respectively. [Figure 9]1 is a Western blot containing block copolymer silk polypeptides isolated from cultures expressing 18B silk polypeptides. [Figure 10] FIG. 2 is a magnified optical microscopy view of a block copolymer fiber produced by the methods described herein. [Figure 11] 1 shows a graph of stress versus strain for several block copolymer fibers made according to the methods described herein. [Figure 12] 1 is an assembly diagram of several SilkR domains to form a block copolymer polynucleotide according to an embodiment of the present invention. [Figure 13] FIG. 1 shows a Western blot of expressed block copolymer polypeptides, each of which is a concatemer of four copies of the indicated silk repeat sequence. [Figure 14] Representative Western blots of expressed silk terminal domain sequences and additional expressed block copolymer polypeptides constructed with silk repeat sequences are shown. [Figure 15] 1 shows an assembly of circular permutants of 18B polypeptide in accordance with an embodiment of the present invention. [Figure 16] Western blots of expressed block copolymer peptides constructed with silk repeat domains consisting of one to six R domains, including circularly permuted variants and variants expressed by different promoters or at different copy numbers. [Figure 17] 1 is a stress-strain curve showing the effect of draw ratio of block copolymer fibers of 18B polypeptide. [Figure 18] 1 is a stress-strain curve for a block copolymer fiber containing SEQ ID NO:1398. [Figure 19] FTIR spectrum results for untreated and annealed block copolymer fibers are shown. [Figure 20] 1 shows a scanning electron micrograph of a block copolymer fiber of the present invention. [Figure 21]FIG. 1 shows a graph depicting the amino acid content of various silk repeat sequences that can be expressed as block copolymers useful for producing fibers. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] Detailed Description of the Invention Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those skilled in the art.Furthermore, unless otherwise required by context, singular terms shall include plurals, and plural terms shall include singulars.In general, the nomenclature and techniques used in connection with biochemistry, enzymology, molecular and cell biology, microbiology, genetics, and polypeptide and nucleic acid chemistry and hybridization described herein are those that are well known and commonly used in the art.
[0018] The methods and techniques of the present invention are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout this specification. For example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989); Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2002); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990); Taylor and Drickamer, Introduction to Glycobiology, Oxford Univ. Press (2003); Worthington Enzyme Manual, Worthington Biochemical Corp., Freehold, NJ; Handbook of Biochemistry: Section A Proteins, Vol I, CRC Press (1976); Handbook of Biochemistry: Section A Proteins, Vol II, CRC Press (1976); Essentials of Glycobiology, Cold Spring Harbor Laboratory Press (1999).
[0019] All publications, patents, and other references mentioned herein are incorporated by reference in their entirety.
[0020] The following terms, unless otherwise indicated, shall be understood to have the following meanings:
[0021] The term "polynucleotide" or "nucleic acid molecule" refers to a polymeric form of nucleotides at least 10 bases in length. The term includes DNA molecules (e.g., cDNA or genomic DNA or synthetic DNA) and RNA molecules (e.g., mRNA or synthetic RNA), including DNA or RNA analogs that contain non-natural nucleotide analogs, non-native internucleoside linkages, or both. Nucleic acids can exist in any topological conformation. For example, nucleic acids can be single-stranded, double-stranded, triple-stranded, quadruple-stranded, partially double-stranded, branched, hairpinned, circular, or padlocked conformation.
[0022] As an example, for all sequences described herein in the general format "SEQ ID NO:," unless otherwise indicated, a "nucleic acid comprising SEQ ID NO:1" refers to a nucleic acid having at least a portion thereof either (i) the sequence of SEQ ID NO:1, or (ii) a sequence complementary to SEQ ID NO:1. The alternative is dictated by the context. For example, if the nucleic acid is used as a probe, the alternative is dictated by the requirement that the probe be complementary to a desired target.
[0023] An "isolated" RNA, DNA, or mixed polymer is one that is substantially separated from other cellular components which naturally accompany the native polynucleotide in its natural host cell, such as ribosomes, polymerases, and naturally associated genomic sequences.
[0024] The term "recombinant" refers to a biological molecule, e.g., a gene or polypeptide, that is (1) removed from its naturally occurring environment, (2) not associated with all or a portion of a polynucleotide found in nature, (3) operably linked to a polynucleotide with which it is not linked in nature, or (4) not found in nature. The term "recombinant" can be used in reference to cloned DNA isolates, chemically synthesized polynucleotide analogs, or biologically synthesized polynucleotide analogs by heterologous systems, as well as polypeptides and / or mRNAs encoded by such nucleic acids.
[0025] As used herein, an endogenous nucleic acid sequence (or its encoded polypeptide product) in the genome of an organism is considered "recombinant" herein when a heterologous sequence is placed adjacent to the endogenous nucleic acid sequence such that the expression of the endogenous nucleic acid sequence is altered. In this context, a heterologous sequence is a sequence that is not naturally adjacent to the endogenous nucleic acid sequence, regardless of whether the heterologous sequence is itself endogenous (originating from the same host cell or its progeny) or exogenous (originating from a different host cell or its progeny). As an example, a promoter sequence can be used in place of the native promoter of a gene in the genome of a host cell (e.g., by homologous recombination) such that the gene has an altered expression pattern. The gene is then "recombinant" because it is separated from at least a portion of the sequences that are naturally adjacent to it. In some embodiments, the heterologous nucleic acid molecule is not endogenous to the organism. In further embodiments, the heterologous nucleic acid molecule is a plasmid or molecule that is integrated into a host chromosome by homologous or random integration.
[0026] A nucleic acid is also considered "recombinant" if it contains any modification that does not naturally occur in the corresponding nucleic acid in a genome. For example, an endogenous coding sequence is considered "recombinant" if it contains an insertion, deletion, or point mutation that has been artificially introduced, e.g., by human intervention. A "recombinant nucleic acid" also includes a nucleic acid integrated into a heterologous site in a host cell chromosome, and a nucleic acid construct that exists as an episome.
[0027] As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence includes a nucleic acid sequence that can be translated according to the standard genetic code to provide the same amino acid sequence as that translated from the reference nucleic acid sequence. The term "degenerate oligonucleotide" or "degenerate primer" is used to refer to an oligonucleotide that can hybridize to a target nucleic acid sequence that is not necessarily identical in sequence but is homologous to each other within one or more specific segments.
[0028] The term "percent sequence identity" or "identical" in the context of nucleic acid sequences refers to the residues in two sequences that are the same when aligned for maximum matching. The length of sequence identity comparison may span a stretch of at least about 9 nucleotides, generally at least about 20 nucleotides, more generally at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, preferably at least about 36 nucleotides, or more nucleotides. There are many different algorithms known in the art that can be used to measure nucleotide sequence identity. For example, polynucleotide sequences can be compared using FASTA, Gap, or Bestfit, which are programs in the Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wis. FASTA provides alignment and percent sequence identity of the region of optimal overlap between the query sequence and the search sequence. Pearson, Methods Enzymol. 183:63-98 (1990) (incorporated herein by reference in its entirety). For example, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (word size 6 and NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1, incorporated herein by reference.Alternatively, sequences can be compared using the computer program BLAST (Altschul et al., J. Mol. Biol. 215:403-410 (1990); Gish and States, Nature Genet. 3:266-272 (1993); Madden et al., Meth. Enzymol. 266:131-141 (1996); Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997); Zhang and Madden, Genome Res. 7:649-656 (1997)), in particular blastp or tblastn (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
[0029] The terms "substantial homology" or "substantial similarity," when referring to a nucleic acid or a fragment thereof, indicate that when optimally aligned with another nucleic acid (or its complementary strand) with appropriate nucleotide insertions or deletions, there is nucleotide sequence identity as measured by well-known sequence identity algorithms such as FASTA, BLAST or Gap, as discussed above, in at least about 76%, 80%, 85%, preferably at least about 90%, and more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases.
[0030] The nucleic acids (also called polynucleotides) of the present invention may include both sense and antisense strands of RNA, cDNA, genomic DNA, as well as synthetic forms and mixed polymers thereof. They may be chemically or biochemically modified or contain non-natural or derivatized nucleotide bases as would be readily recognized by those skilled in the art. Such modifications include, for example, labels, methylation, substitution with one or more analogs of naturally occurring nucleotides, uncharged linkages (e.g., methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendant moieties (e.g., polypeptides), intercalators (e.g., acridines, psoralens, etc.), chelators, alkylators, and internucleotide modifications such as modified linkages (e.g., alpha anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a specified sequence via hydrogen bonds and other chemical interactions. Such molecules are known in the art and include, for example, those in which the phosphate linkages in the backbone of the molecule are replaced with peptide linkages. Other modifications can include, for example, analogs in which the ribose ring contains bridging moieties or other structures such as the modifications found in "locked" nucleic acids.
[0031] The term "mutated" as applied to a nucleic acid sequence means that nucleotides within a nucleic acid sequence may be inserted, deleted, or changed compared to a reference nucleic acid sequence. A single change may be made at one locus (point mutation), or multiple nucleotides may be inserted, deleted, or changed at a single locus. Furthermore, one or more changes may be made at any number of loci within a nucleic acid sequence. Nucleic acid sequences can be mutated by any method known in the art, including, but not limited to, mutagenesis techniques such as "error-prone PCR" (a method in which PCR is performed under conditions of low fidelity of DNA polymerase copying, such that a high percentage of point mutations are obtained over the entire length of the PCR product; see, e.g., Leung et al., Technique, 1:11-15 (1989) and Caldwell and Joyce, PCR Methods Applic. 2:28-33 (1992)); and "oligonucleotide-directed mutagenesis" (a method that allows for the generation of site-specific mutations in a cloned DNA segment of interest; see, e.g., Reidhaar-Olson and Sauer, Science 241:53-57 (1988)).
[0032] The term "vector" as used herein is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid linked thereto. One type of vector is a "plasmid", which generally refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated, but also includes linear double-stranded molecules, such as those obtained from amplification by polymerase chain reaction (PCR) or from treating a circular plasmid with a restriction enzyme. Other vectors include cosmids, bacterial artificial chromosomes (BACs), and yeast artificial chromosomes (YACs). Another type of vector is a viral vector (described in more detail below), into which additional DNA segments can be ligated into a viral genome. Some vectors can replicate autonomously within a host cell into which they are introduced (e.g., vectors with an origin of replication that functions in the host cell). Other vectors can be integrated into the genome of the host cell when introduced into the host cell, thereby replicating along with the host genome. In addition, certain preferred vectors can direct the expression of genes operably linked thereto. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors").
[0033] The term "expression system" as used herein includes vehicles or vectors for the expression of a gene in a host cell as well as vehicles or vectors that effect stable integration of the gene into the host chromosome.
[0034] "Operatively linked" or "operably linked" expression control sequences refer to a linkage in which the expression control sequences are contiguous with a gene of interest such that they control the gene of interest, and also refer to expression control sequences that act in trans or at some distance to control the gene of interest.
[0035] The term "expression control sequence" as used herein refers to a polynucleotide sequence necessary to affect the expression of the coding sequence that is functionally linked thereto. Expression control sequence is a sequence that controls the transcription, post-transcriptional events, and translation of nucleic acid sequence. Expression control sequence includes appropriate transcription initiation sequence, termination sequence, promoter sequence, and enhancer sequence; signals for efficient RNA processing, such as splicing signal and polyadenylation signal; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding site); sequences that enhance polypeptide stability; and optionally sequences that enhance polypeptide secretion. The nature of such control sequence varies depending on the host organism; in prokaryotes, such control sequence generally includes promoter, ribosome binding site, and transcription termination sequence. The term "control sequence" is intended to include, at a minimum, all components whose presence is essential for expression, and may also include additional components whose presence is advantageous, such as leader sequences and fusion partner sequences.
[0036] The term "promoter," as used herein, refers to a DNA region to which RNA polymerase binds to initiate gene transcription, located 5' to the mRNA transcription start site.
[0037] The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant vector has been introduced. Such terms are intended to refer not only to the particular subject cell, but also to the progeny of such a cell. In successive generations, certain modifications may occur, either by mutation or environmental influences, so that such progeny may not in fact be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. A recombinant host cell may be an isolated cell or cell line grown in culture, or may be a cell belonging to a living tissue or organism.
[0038] The term "peptide" as used herein refers to short polypeptides, e.g., typically less than about 50 amino acids in length, more typically less than about 30 amino acids in length. The term, as used herein, encompasses analogs and mimetics that mimic structural and thus biological function.
[0039] The term "polypeptide" encompasses both naturally occurring and non-naturally occurring proteins, as well as fragments, variants, derivatives, and analogs thereof. A polypeptide may be monomeric or polymeric. Furthermore, a polypeptide may contain multiple distinct domains, each having one or more distinct activities.
[0040] As used herein, the term "molecule" means any compound, including but not limited to small molecules, peptides, polypeptides, sugars, nucleotides, nucleic acids, polynucleotides, lipids, etc., and such compounds may be natural or synthetic.
[0041] The term "block" or "repeat unit" as used herein refers to a subsequence of more than about 12 amino acids of a natural silk polypeptide that is found repeatedly in the natural silk polypeptide sequence, possibly with slight variations, and serves as a basic repeat unit in the silk polypeptide sequence. Examples can be found in Table 1. Further examples of block amino acid sequences can be found in SEQ ID NOs: 1515-2156. A block may, but does not necessarily, contain a very short "motif." A "motif," as used herein, refers to a sequence of about 2-10 amino acids that occurs in multiple blocks. For example, a motif can consist of the amino acid sequence GGA, GPG, or AAAAA (SEQ ID NO: 2803). A sequence of multiple blocks is a "block copolymer."
[0042] As used herein, the term "repeat domain" refers to a sequence selected from a set of continuous (uninterrupted by substantially non-repeat domains, excluding known silk spacer elements) repeat segments in silk polypeptides. A natural silk sequence generally contains one repeat domain. In some embodiments of the present invention, there is one repeat domain per silk molecule. A "macro-repeat" as used herein is a naturally occurring repeat amino acid sequence that contains more than one block. In some embodiments, the macro-repeat is repeated at least twice in the repeat domain. In further embodiments, the two repeats are imperfect. A "quasi-repeat" as used herein is an amino acid sequence that contains more than one block, such that the amino acid sequences of the blocks are similar but not identical.
[0043] "Repeat sequence" or "R" as used herein refers to a repeated amino acid sequence. Examples include the nucleotide sequences of SEQ ID NOs: 1-467, the nucleotide sequences with flanking sequences for cloning of SEQ ID NOs: 468-931, and the amino acid sequences of SEQ ID NOs: 932-1398. In some embodiments, the repeat sequence comprises a macrorepeat or a fragment of a macrorepeat. In other embodiments, the repeat sequence comprises a block. In further embodiments, a single block is split across two repeat sequences.
[0044] Any range disclosed herein includes the ends of the range, for example, the range 2 to 5% includes 2% and 5%, and any number or fraction of a number therebetween, such as: 2.25%, 2.5%, 2.75%, 3%, 3.25%, 3.5%, 3.75%, 4%, 4.25%, 4.5%, and 4.75%.
[0045] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Exemplary methods and materials are described below, but methods and materials similar or equivalent to those described herein can also be used in the practice of this invention and will be apparent to those skilled in the art. All publications and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will govern. The materials, methods, and examples are illustrative only and are not intended to be limiting.
[0046] Throughout this specification and the claims, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integers or groups of integers.
[0047] Silk Array In some embodiments, disclosed herein are 1) block copolymer polypeptide compositions made by mixing and combining repeat domains from silk polypeptide sequences, and 2) recombinant expression of block copolymer polypeptides with a size (approximately 40 kDa) large enough to form useful fibers by secretion from industrially scalable microorganisms. The inventors herein provide the ability to produce relatively large (approximately 40 kDa to approximately 100 kDa) block copolymer polypeptides engineered from silk repeat domain fragments, including sequences from nearly all published amino acid sequences of spider silk polypeptides, in scalable engineered microbial hosts. In some embodiments, silk polypeptide sequences are combinatorially engineered to produce highly expressed and secreted polypeptides capable of fiber formation.
[0048] In some embodiments, compositions are provided herein for the expression and secretion of block copolymers engineered from combinatorial mixes of silk polypeptide domains across silk polypeptide sequence space.In some embodiments, methods are provided herein for secreting block copolymers in expandable organisms (e.g., yeast, fungi, and gram-positive bacteria).In some embodiments, the block copolymer polypeptide comprises zero or one or more N-terminal domains (NTDs), one or more repeat domains (REPs), and zero or one or more C-terminal domains (CTDs).In some aspects of the embodiment, the block copolymer polypeptide is a single polypeptide chain of >100 amino acids. In some embodiments, the block copolymer polypeptide comprises a domain that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence of SEQ ID NOs: 932-1398.
[0049] Several types of natural spider silk have been identified, and the mechanical properties of each naturally spun silk type are thought to be closely related to the molecular composition of the silk. See, e.g., Garb, JE, et al., Untangling spider silk evolution with spidroin terminal domains, BMC Evol. Biol., 10:243 (2010); Bittencourt, D., et al., Protein families, natural history and biotechnological aspects of spider silk, Genet. Mol. Res., 11:3 (2012); Rising, A., et al., Spider silk proteins: recent advances in recombinant production, structure-function relationships and biomedical applications, Cell. Mol. Life Sci., 68:2, pg. 169-184 (2011); and Humenik, M., et al., Spider silk: understanding the structure-function relationship of a natural fiber, Prog. Mol. Biol. Transl. Sci., 103, pg. 131-85 (2011).
[0050] AcSp silks tend to have high toughness, resulting from moderately high strength in addition to moderately high extensibility. AcSp silks are characterized by large block ("ensemble repeat") sizes that often incorporate polyserine and GPX motifs. Tubular (TuSp or Cylindrical) silks tend to have large diameters with moderate strength and high extensibility. TuSp silks are characterized by their polyserine and polythreonine content, as well as short tracts of polyalanine. Major ampullate (MaSp) silks tend to have high strength and moderate extensibility. MaSp silks can be one of two subtypes: MaSp1 and MaSp2. MaSp1 silks are generally less extensible than MaSp2 silks and are characterized by polyalanine, GX, and GGX motifs. MaSp2 silk is characterized by polyalanine, GGX, and GPX motifs. MiSp silk tends to have moderate strength and moderate extensibility. MiSp silk is characterized by GGX, GA, and polyA motifs and often contains a spacer element of approximately 100 amino acids. Flagellate silk (Flag) silk tends to have very high extensibility and moderate strength. Flag silk is usually characterized by GPG, GGX, and a short spacer motif.
[0051] The properties of each silk type may vary between species, and spiders that lead distinct lifestyles (e.g., resident web spinners versus wandering hunters) or are evolutionarily older may produce silks with properties that differ from those described above (for a description of spider diversity and classification, see Hormiga, G., and Griswold, CE, Systematics, phylogeny, and evolution of orb-weaving spiders, Annu. Rev. Entomol. 59, pg. 487-512 (2014); and Blackedge, TA et al., Reconstructing web evolution and spider diversification in the molecular era, Proc. Natl. Acad. Sci. USA, 106:13, pg. 5229-5234 (2009)). However, synthetic block copolymer polypeptides that have sequence similarity and / or amino acid composition similarity to the repeat domains of natural silk proteins can be used to produce consistent silk-like fibers on a commercial scale that recapitulate the properties of the corresponding natural silk fibers.
[0052] In some embodiments, a list of putative silk sequences can be compiled by searching GenBank for related terms, e.g., "spidroin," "fibroin," "MaSp," and the sequences can be pooled with additional sequences obtained by independent sequencing efforts. The sequences are then translated into amino acids, filtered for duplicate entries, and manually divided into domains (NTD, REP, CTD). In some embodiments, the candidate amino acid sequences are back-translated into DNA sequences optimized for expression in Pichia (Komagataella) pastoris. The DNA sequences are each cloned into an expression vector and transformed into Pichia (Komagataella) pastoris. In some embodiments, various silk domains that show successful expression and secretion are then assembled in a combinatorial manner to construct silk molecules capable of fiber formation.
[0053] Silk polypeptides are characterized by being composed of repeat domains (REPs) flanked by non-repetitive regions (e.g., C-terminal and N-terminal domains). In certain embodiments, both the C-terminal and N-terminal domains are 75-350 amino acids long. The repeat domains exhibit a hierarchical structure, as shown in FIG. 1. The repeat domains contain a series of blocks (also called repeat units). The blocks are repeated, sometimes perfectly and sometimes imperfectly (making up pseudo-repeat domains), throughout the silk repeat domain. The length and composition of the blocks vary among different silk types and among different species. Table 1 lists examples of block sequences from selected species and silk types, and further examples are shown in Rising, A. et al., Spider silk proteins: recent advances in recombinat production, structure-function relationships and biomedical applications, Cell Mol. Life Sci., 68:2, pg 169-184 (2011); and Gatesy, J. et al., Extreme diversity, conservation, and convergence of spider silk fibroin sequences, Science, 291:5513, pg. 2603-2605 (2001). In some cases, the blocks may be arranged in a regular pattern to form larger macrorepeats that occur multiple times (usually 2-8 times) in the repeat domain of the silk sequence. Repeated blocks within a repeat domain or macrorepeat, and macrorepeats within a repeat domain, may be separated by spacing elements. In some embodiments, the block sequence comprises a glycine-rich region followed by a polyA region. In some embodiments, a short (about 1-10) amino acid motif occurs multiple times within the block. A subset of commonly observed motifs is shown in FIG.For the purposes of the present invention, blocks from different natural silk polypeptides can be selected without regard to circular permutation (i.e., identified blocks that are otherwise similar between silk polypeptides may not align due to circular permutation). Thus, for example, the "block" SGAGG (SEQ ID NO: 2804) is, for the purposes of the present invention, the same as GSGAG (SEQ ID NO: 2805), which is also the same as GGSGA (SEQ ID NO: 2806); they are all just circular permutations of each other. The particular permutation selected for a given silk sequence may be dictated by convenience more than anything else (usually starting with G). Silk sequences obtained from the NCBI database can be partitioned into blocks and non-repetitive regions.
[0054] (Table 1) Sample of block arrangement TIFF2024155944000002.tif246158TIFF2024155944000003.tif246158
[0055] The construction of fiber-forming block copolymer polypeptides from blocks and / or macro-repeat domains according to certain embodiments of the invention is shown in Figures 2 and 3. Figure 2 shows the division of silk sequences into separate domains. A native silk sequence 200, obtained from a protein database such as GenBank or by de novo sequencing, is broken down into domains (N-terminal domain 202, repeat domain 204, and C-terminal domain 206). The N-terminal domain 202 and C-terminal domain 206 sequences selected for the purpose of synthesis and assembly into fibers contain native amino acid sequence information and other modifications described herein. The repeat domain 204 is broken down into repeat sequences 208 containing representative blocks, usually 1-8 depending on the type of silk, which captures important amino acid information while reducing the size of the DNA encoding the amino acids into easily synthesizable fragments. 3 illustrates how selected NTs 202, CTs 206, and repeat sequences 208 can be assembled to create block copolymer polypeptides that can be purified into fibers that mimic the functional properties of silk, as described in embodiments of the present invention. Individual NTs, CTs, and repeat sequences that are identified as expressed and secreted are assembled into functional block copolymer polypeptides. In some embodiments, a properly formed block copolymer polypeptide comprises at least one repeat domain that includes at least one repeat sequence 208, optionally adjacent to the N-terminal domain 202 and / or C-terminal domain 206.
[0056] In some embodiments, the repeat domain comprises at least one repeat sequence. In some embodiments, the repeat sequence, the N-terminal domain sequence, and / or the C-terminal domain sequence are selected from SEQ ID NOs: 932-1398. In some embodiments, the repeat sequence is 150-300 amino acid residues. In some embodiments, the repeat sequence comprises multiple blocks. In some embodiments, the repeat sequence comprises multiple macro-repeats. In some embodiments, the block or macro-repeat is split across multiple repeat sequences.
[0057] In some embodiments, to meet DNA assembly requirements, the repeat sequence begins with glycine and cannot end with phenylalanine (F), tyrosine (Y), tryptophan (W), cysteine (C), histidine (H), asparagine (N), methionine (M), or aspartic acid (D). In some embodiments, a portion of the repeat sequence may be altered compared to the native sequence. In some embodiments, the repeat sequence may be altered, such as by adding a serine to the C-terminus of the polypeptide (to avoid ending with F, Y, W, C, H, N, M, or D). In some embodiments, the repeat sequence may be modified by filling in an incomplete block with a homologous sequence from another block. In some embodiments, the repeat sequence may be modified by rearranging the order of the blocks or macrorepeats.
[0058] In some embodiments, non-repetitive N- and C-terminal domains can be selected for synthesis (see SEQ ID NOs: 1-145). In some embodiments, the N-terminal domain can be due to removal of a leading signal sequence, for example, as identified by SignalP (Peterson, TN, et. Al., SignalP 4.0: discriminating signal peptides from transmembrane regions, Nat. Methods, 8:10, pg. 785-786 (2011)).
[0059] In some embodiments, the N-terminal domain, repeat sequence, or C-terminal domain sequence is selected from the group consisting of Agelenopsis aperta, Aliatypus gulosus, Aphonopelma seemanni, Aptostichus sp. AS217, Aptostichus sp. AS220, Araneus diadematus, Araneus gemmoides, Araneus ventricosus, Argiope amoena, Argiope argentata, Argiope bruennichi, Argiope trifasciata, Argiope trifasciata, Atypoides riversi, Avicularia juruensis, Bothriocyrtum californicum, Deinopis spinosa, Diguetia canities, Dolomedes tenebrosus, Euagrus chisoseus, Euprosthenops australis, Gasteracantha mammosa, Hypochilus thorelli, Kukulcania hibernalis, Latrodectus hesperus hesperus, Megahexura fulva, Metepeira grandiosa, Nephila antipodiana, Nephila clavata, Nephila clavipesclavipes, Nephila madagascariensis, Nephila pilipes, Nephilengys cruentata, Parawixia bistriata, Peucetia viridans, Plectreurys tristis, Poecilotheria regalis, Tetragnatha kauaiensis, or Uloborus diversus.
[0060] In some embodiments, the silk polypeptide nucleotide coding sequence can be operably linked to an α-mating factor nucleotide coding sequence. In some embodiments, the silk polypeptide nucleotide coding sequence can be operably linked to another endogenous or heterologous secretion signal coding sequence. In some embodiments, the silk polypeptide nucleotide coding sequence can be operably linked to a 3X FLAG nucleotide coding sequence. In some embodiments, the silk polypeptide nucleotide coding sequence is operably linked to another affinity tag, such as 6-8 His residues (SEQ ID NO: 2824).
[0061] Expression vector The expression vector of the present invention can be produced according to the teachings of the present specification, taking into account the techniques known in the art.Sequences, such as vector sequences or sequences encoding transgenes, can be obtained commercially from companies such as Integrated DNA Technologies, Coralville, IA, or DNA 2.0, Menlo Park, CA.Exemplary expression vectors directing high-level expression of chimeric silk polypeptides are provided herein.
[0062] Another standard source of polynucleotides used in the present invention is polynucleotides isolated from organisms (e.g., bacteria), cells, or selected tissues. Nucleic acids from selected sources can be isolated by standard procedures, which typically include sequential phenol and phenol / chloroform extractions followed by ethanol precipitation. After precipitation, polynucleotides can be treated with restriction endonucleases that cut the nucleic acid molecules into fragments. To provide starting material of appropriate size for cloning, fragments of selected size can be separated by a number of techniques, including agarose or polyacrylamide gel electrophoresis or pulsed field gel electrophoresis (Care et al. (1984) Nuc. Acid Res. 12:5647-5664; Chu et al. (1986) Science 234:1582; Smith et al. (1987) Methods in Enzymology 151:461).
[0063] Another method to obtain the nucleotide components of an expression vector or construct is PCR. The general procedure for PCR is taught in MacPherson et al., PCR: A PRACTICAL APPROACH, (IRL Press at Oxford University Press, (1991)). PCR conditions for each application reaction can be empirically determined. Many parameters affect the success of the reaction. These parameters include annealing temperature and time, extension time, Mg2+ and ATP concentrations, pH, and the relative concentrations of primers, templates, and deoxyribonucleotides. Exemplary primers are described below in the Examples. After amplification, the resulting fragments can be detected by agarose gel electrophoresis, followed by visualization with ethidium bromide staining and ultraviolet illumination.
[0064] Another method for obtaining polynucleotides is by enzymatic digestion. For example, a nucleotide sequence can be generated by digestion of a suitable vector with a suitable recognition restriction enzyme. The restriction cleaved fragment can be blunt-ended by treatment with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of four deoxynucleotide triphosphates (dNTPs) using standard techniques.
[0065] Polynucleotides are inserted into suitable backbones, such as plasmids, using methods well known in the art. For example, insert and vector DNA can be contacted with restriction enzymes under suitable conditions to create complementary or blunt ends on each molecule, which can pair with each other and be linked with ligase. Alternatively, synthetic nucleic acid linkers can be ligated to the ends of the polynucleotides. These synthetic linkers can contain nucleic acid sequences that correspond to specific restriction sites in the vector DNA. Other means are also known and available in the art. A variety of sources can be used for the component polynucleotides.
[0066] In some embodiments, an expression vector containing an R, N, or C sequence is transformed into a host organism for expression and secretion. In some embodiments, the expression vector contains a secretion signal. In some embodiments, the expression vector contains a terminator signal. In some embodiments, the expression vector is designed to integrate into the host cell genome and contains: a region of homology with the target genome, a promoter, a secretion signal, a tag (e.g., a Flag tag), a termination / polyA signal, a selectable marker for Pichia, a selectable marker for E. coli, an origin of replication for E. coli, and a restriction site for releasing the fragment of interest.
[0067] Host cell transformants In some embodiments of the invention, host cells transformed with a nucleic acid molecule or vector of the invention, and their progeny, are provided. In some embodiments of the invention, these cells carry the nucleic acid sequence of the invention on the vector and are free to replicate the vector, but are not required to do so. In other embodiments of the invention, the nucleic acid is integrated into the genome of the host cell.
[0068] In some embodiments, microorganisms or host cells that enable large-scale production of the block copolymer polypeptides of the invention comprise a combination of the following: 1) the ability to produce large (>75 kDa) polypeptides, 2) the ability to secrete the polypeptide outside the cell to avoid expensive downstream intracellular purification, 3) resistance to contaminants (e.g., viral and bacterial contamination) at large scale, and 4) the existing know-how to grow and process the organisms at large scale (1-2000 m 3 ) bioreactor.
[0069] A variety of host organisms can be modified / transformed to contain the block copolymer polypeptide expression system. Preferred organisms for expression of recombinant silk polypeptides include yeast, fungi, and gram-positive bacteria. In certain embodiments, the host organism is selected from the group consisting of Arxula adeninivorans, Aspergillus aculeatus, Aspergillus awamori, Aspergillus ficuum, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Aspergillus sojae, Aspergillus tubigensis, Bacillus alcalophilus, and the like. alkalophilus, Bacillus amyloliquefaciens, Bacillus anthracis, Bacillus brevis, Bacillus circulans, Bacillus coagulans, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus methanolicus, Bacillus stearothermophilus, Bacillus subtilis, Bacillus thuringiensis, Candida boidinii boidinii, Chrysosporium lucnowenselucknowense, Fusarium graminearum, Fusarium venenatum, Kluyveromyces lactis, Kluyveromyces marxianus, Myceliopthora thermophila, Neurospora crassa, Ogataea polymorpha, Penicillium camemberti, Penicillium canescens, Penicillium chrysogenum, Penicillium emersonii emersonii, Penicillium funiculosum, Penicillium griseoroseum, Penicillium purpurogenum, Penicillium roqueforti, Phanerochaete chrysosporium, Pichia angusta, Pichia methanolica, Pichia (komagatella) pastoris, Pichia polymorpha, Pichia stipitis, Rhizomucor miehei, Rhizomucor pusillus pusillus, Rhizopus arrhizus, Streptomyces lividans, Saccharomyces cerevisiae, Schwanniomyces occidentalisoccidentalis, Trichoderma harzianum, Trichoderma reesei, or Yarrowia lipolytica.
[0070] In a preferred aspect, the method provides for culturing the host cells for direct product secretion for easy recovery without the need to extract biomass. In some embodiments, the block copolymer polypeptide is secreted directly into the medium for collection and processing.
[0071] Polypeptide Purification The recombinant block copolymer polypeptide based on spider silk sequence produced by gene expression in recombinant prokaryotic or eukaryotic system can be purified according to methods known in the art. In a preferred embodiment, a commercially available expression / secretion system can be used, whereby recombinant polypeptide is expressed and then secreted from host cells and easily purified from the surrounding medium. If no expression / secretion vector is used, an alternative approach involves purifying recombinant block copolymer polypeptide from cell lysate (cell debris after destruction of cell integrity) derived from prokaryotic or eukaryotic cells in which the polypeptide is expressed. Methods for making such cell lysates are known to those skilled in the art. In some embodiments, recombinant block copolymer polypeptide is isolated from cell culture supernatant.
[0072] The recombinant block copolymer polypeptide may be purified by affinity separation, for example, immunological interaction with an antibody that specifically binds to the recombinant polypeptide, or by nickel columns for the isolation of recombinant polypeptides tagged with 6-8 histidine residues at the N- or C-terminus. Alternative tags may include the FLAG epitope or the hemagglutinin epitope. Such methods are commonly used by those of skill in the art.
[0073] In addition, the method of the present invention may preferably include a purification method comprising exposing the cell culture supernatant containing the expressed block copolymer polypeptide to ammonium sulfate at 5 to 60% saturation, preferably 10 to 40% saturation.
[0074] Spinning to make fibers In some embodiments, the solution of the block copolymer polypeptide of the present invention is spun into fibers using elements of processes known in the art. These processes include, for example, wet spinning, dry wet spinning, and dry spinning. In a preferred wet spinning embodiment, the filaments are extruded through an orifice into a liquid coagulation bath. In one embodiment, the filaments can be extruded through an air gap before contacting the coagulation bath. In the dry wet spinning method, the spinning solution is attenuated and stretched in an inert non-coagulating fluid, such as air, before entering the coagulation bath. The appropriate coagulation fluid is the same as that used in the wet spinning method.
[0075] A preferred coagulation bath for wet spinning is maintained at a temperature of 0-90°C, more preferably 20-60°C, and is preferably about 60%, 70%, 80%, 90%, or even 100% alcohol, preferably isopropanol, ethanol, or methanol. In a preferred embodiment, the coagulation bath is 85:15 volume percent methanol:water. In an alternative embodiment, the coagulation bath contains ammonium sulfate, sodium chloride, sodium sulfate, or other protein precipitating salts at a temperature of 20-60°C. Certain coagulant baths may be preferred depending on the composition of the dope solution and the desired fiber properties. For example, salt-based coagulant baths are preferred for aqueous dope solutions. For example, methanol is preferred for producing circular cross-section fibers. Residence times in the coagulation bath can range from nearly instantaneous to several hours, with preferred residence times lasting one minute or less, and more preferred residence times lasting about 20-30 seconds. Residence times may depend on the shape of the extruded fiber or filament. In some embodiments, the extruded filament or fiber is passed through two or more coagulation baths of different or the same composition. Optionally, the filament or fiber is also passed through one or more rinse baths to remove residual solvent and / or coagulant. The salt or alcohol baths are preferably followed by rinse baths that reduce the salt or alcohol concentration, preferably until a final water bath.
[0076] After extrusion, the filaments or fibers may be stretched. The stretching may improve the consistency, axial orientation and toughness of the filaments. The stretching may be enhanced by the composition of the coagulation bath. The stretching may also be performed in a stretching bath containing a plasticizer such as water, glycerol or a salt solution. The stretching may also be performed in a stretching bath containing a crosslinking agent such as gluteraldehyde or formaldehyde. The stretching may be performed at a temperature between 25 and 100°C, preferably at 60°C, to alter the fiber properties. As is common in continuous processing, the stretching may be performed simulationeously during the coagulation, washing, plasticization and / or crosslinking procedures described above. The stretching rate depends on the filament being processed. In one embodiment, the stretching rate is preferably about 5 times the rate of reeling from the coagulation bath.
[0077] In one embodiment of the invention, the filaments are wound onto a spool after extrusion or drawing, the winding speed generally being between 1 and 500 m / min, preferably between 10 and 50 m / min.
[0078] In other embodiments, the filaments may be coated with a lubricant or finish prior to winding to facilitate easy fiber processing. Suitable lubricants or finishes may be polymeric or waxy finishes, such as, but not limited to, mineral oil, fatty acids, isobutyl stearate, 2-ethylhexyl tallow fatty acid esters, polyol carboxylic acid esters, coconut oil fatty acid esters of glycerol, alkoxylated glycerol, silicones, dimethylpolysiloxanes, polyalkylene glycols, polyethylene oxides, and propylene oxide copolymers.
[0079] The spun fibers produced by the method of the invention may have a variety of physical properties and characteristics depending on the initial properties of the raw material (i.e., dope solution) and the adjustment and selection of variable aspects of the method performed to achieve the desired end product (whether that product is a soft, viscous, pliable matrix conducive to cell growth in medical applications or a load-bearing elastic fiber such as fishing line or cable). The tensile strength of filaments spun by the method of the invention generally ranges from 0.2 g / denier (or g / (g / 9000 m)) to 3 g / denier, with filaments intended for load-bearing uses preferably exhibiting a tensile strength of at least 2 g / denier. In some embodiments, the fibers have a fineness of 0.2 to 0.6 denier. Properties such as elasticity and elongation at break will vary depending on the intended use of the spun fibers, but the elasticity is preferably 5% or more, and for uses where elasticity is important, e.g., for products that can be "tied" such as sutures or lace, the elasticity is preferably 10% or more. The water retention of the spun fibers is preferably close to that of natural silk fibers, i.e. 10%. The diameter of the spun fibers may range over a wide range depending on the application, with preferred fiber diameters ranging from 5, 10, 20, 30, 40, 50, 60 microns, although substantially thicker fibers may be produced, particularly for industrial applications (e.g., cables). The cross-sectional characteristics of the spun fibers may vary, for example, preferred spun fibers include spun fibers characterized by circular cross-sections, elliptical, star-shaped cross-sections, and other core / sheath cross-sections, as well as hollow fibers. EXAMPLES
[0080] Example 1 Obtaining silk sequences Silk sequences and partial sequences were obtained by searching the NCBI nucleotide database to identify spider silks using the following terms: MaSp, TuSp, CySp, MiSp, AcSp, Flag, major ampullate gland, minor ampullate gland, flagellate gland, botryoid gland, tubular gland, columnar gland, spidroin, and spider fibroin. The obtained nucleotide sequences were translated into amino acid sequences and then curated to remove repeated sequences. Depending on the type of silk, sequences that were less than 200-500 amino acids in length were removed. The silk sequences from the above search were partitioned into blocks (e.g., repetitive sequences) and non-repetitive regions.
[0081] Repeated polypeptide sequences (repeat (R) sequences) were selected from each silk sequence and are listed as SEQ ID NOs: 1077-1393. Parts of the R sequences were modified, for example by adding a serine to the C-terminus, so that the sequence does not end with an F, Y, W, C, H, N, M, or D amino acid. This allows for incorporation into the vector system described below. We also modified incomplete blocks by incorporation of a segment from a homologous sequence from another block. For some sequences in SEQ ID NOs: 1077-1393, the order of the blocks or macrorepeats was changed from the sequence found in the NCBI database to create pseudo-repeat domains.
[0082] A non-repetitive N-terminal domain sequence (N-sequence) and a C-terminal domain sequence (C-sequence) were also selected from each silk sequence (SEQ ID NOs: 932-1076). The N-terminal domain sequence was altered by removal of the leading signal sequence and, if not already present, by the addition of an N-terminal glycine residue.
[0083] Although a number of embodiments of the invention have been described, it will be understood that various modifications can be made without departing from the spirit and scope of the invention.
[0084] Example 2 Reverse translation of silk polypeptide sequences into nucleotide sequences The R, N, and C amino acid sequences described in Example 1 were reverse translated into nucleotide sequences. To perform the reverse translation, 10,000 candidate sequences were generated by using Pichia (Comagatela) pastoris codon usage to bias random selection of the codon encoding the desired amino acid at each position. Selected restriction sites (BsaI, BbsI, BtgZI, AscI, SbfI) were then removed from each sequence; if no sites could be removed, the sequence was discarded. The entropy, the longest repeated subsequence, and the number of repeated 15-mers were then determined for each sequence, respectively.
[0085] To select the optimal sequence from each set of 10,000 to use in synthesis, the following criteria were applied successively: keep the sequence with the lowest 25% of the longest repeated subsequences, keep the sequence with the highest 10% of sequence entropy, and use the sequence with the lowest number of repeated 15-mers.
[0086] Example 3 Screening of silk polypeptides from selected N, C, or R sequences The nucleotide sequences from Examples 1 and 2 were flanked during synthesis by the following sequences to allow cloning: TIFF2024155944000004.tif5144 where "silk" is a polynucleotide sequence selected in accordance with the teachings of Example 2.
[0087] The resulting DNA was digested with BbsI and ligated into either expression vector RM618 (SEQ ID NO:1399) or expression vector RM652 (SEQ ID NO:1400) that had been digested with BtgZI and treated with calf intestinal alkaline phosphatase. The ligated material was transformed into E. coli for clonal isolation and DNA amplification using standard methods.
[0088] Pichia (comagathera) pastoris Expression vectors containing the R, N, or C sequences were transformed into Pichia (Komagatela) pastoris (strain RMs71; which is strain GS115 (NRRL Y15851) with a mutation in the HIS4 gene that was reverted to wild type by transformation with a fragment of the wild type genome (NRRLY 11430) and selection on defined agar plates lacking histidine) using the PEG method (Cregg, JM, DNA-mediated transformation, Methods Mol. Biol., 389, pg. 27-42 (2007)). The expression vector consisted of the targeting region (HIS4), a dominant resistance marker (conferring resistance to nat-nourseothricin), a promoter (pGAP), a secretion signal (alpha mating factor leader and prosequence), and a terminator (pAOX1 pA signal).
[0089] Transformants were plated onto YPD agar plates containing 25 μg / ml nourseothricin and incubated at 30° C. for 48 hours. Two clones from each transformation were inoculated into 400 μl of YPD in a 96-well square well block and incubated at 30° C. for 48 hours with agitation at 1000 rpm. Cells were pelleted by centrifugation and supernatants were collected for analysis of silk polypeptide content by Western blot. The data obtained demonstrate a range of expression and secretion phenotypes, ranging from undetectable polypeptide levels in the supernatant to strong signals on Western blots indicating relatively high titers.
[0090] Successful polypeptide expression and secretion was judged by Western blot. Each Western lane was scored as 1: no band, 2: moderate band, or 3: strong band. The higher of the two scores for each clone was recorded. Representative Western blots with construct numbers are shown in Figures 4 and 5, and additional Western blots for representative clones are shown in Figure 14. A complete list of all R, N, and C sequences tested with Western blot results is shown in Table 2. Silk polypeptides from multiple species, encompassing each gland category and all domain types, were successfully expressed.
[0091] Table 2 Silk polypeptide sequences TIFF2024155944000005.tif169164TIFF2024155944000006.tif245170TIFF2024155944000007.t if241157TIFF2024155944000008.tif242169TIFF2024155944000009.tif242166TIFF20241559440 00010.tif242164TIFF2024155944000011.tif244168TIFF2024155944000012.tif242167TIFF202 4155944000013.tif242169TIFF2024155944000014.tif245169TIFF2024155944000015.tif160169
[0092] Example 4 Amplification of N, R, and C sequences for insertion into assembly vectors DNA for the N, R, and C sequences were PCR amplified from the expression vector and ligated into the assembly vector using the AscI / SbfI restriction sites.
[0093] The forward primer consisted of the following sequence: TIFF2024155944000016.tif5128+ First 19 bp of N, R, or C sequence.
[0094] The reverse primer should be the last 17 bp + It consists of TIFF2024155944000017.tif5130.
[0095] For example, the following array: For TIFF2024155944000018.tif56159, the primers used were: forward: TIFF2024155944000019.tif13165 Reverse: TIFF2024155944000020.tif13152.
[0096] The PCR reaction solution consisted of 12.5 μL 2x KOD Extreme Buffer, 0.25 μl KOD Extreme Hot Start Polymerase, 0.5 μl 10 μM Fwd oligo, 0.5 μl 10 μM Rev oligo, 5 ng template DNA (expression vector), 0.5 μl of 10 mM dNTPs, and ddH2O added to a final volume of 25 μl. The reaction was then thermocycled according to the following program: 1. Denature at 94°C for 5 minutes 2. Denature at 94°C for 30 seconds 3. Anneal at 55°C for 30 seconds. 4. Extend at 72°C for 30 seconds. 5. Repeat steps 2-4 for 29 additional cycles. 6. Final extension at 72°C for 5 min
[0097] The resulting PCR product was digested with the restriction enzymes AscI and SbfI to produce the assembly vector (see explanation in Example 5), TIFF2024155944000021.tif20159, which had been digested with the same enzymes to release the unwanted insert using routine methods.
[0098] Example 5 Synthesis of Silk from Argiope bruenichii MaSp2 Blocks (RM439, "18B") Using the algorithm described in Example 2, a set of six repeat blocks (or block copolymers) from Argiope bruenichii MaSp2 was selected and divided into two R sequences, each consisting of three blocks. The two 3-block R sequences were then synthesized from short oligonucleotides as follows.
[0099] Synthesis of RM409 sequence: The Argiope bruenichii MaSp2 block sequence was generated using a different method than that used in Example 3. Oligos RM2919-RM2942 (SEQ ID NO: 1468-1491) in Table 3 were combined into a single mixture with equal amounts of each oligo (100 μM total). These oligos were phosphorylated in a phosphorylation reaction prepared by combining 1 μl 10x NEB T4 DNA ligase buffer, 1 μl 100 μM pooled oligos, 1 μl NEB T4 polynucleotide kinase (10,000 U / ml), and 7 μl ddH2O and incubating at 37°C for 1 hour. These oligos were then annealed by mixing 4 μl of the phosphorylation reaction with 16 μl ddH2O, heating the mixture to 95°C for 5 minutes, and then cooling the mixture to 25°C at a rate of 0.1°C / sec. These oligos were then ligated together into the vector by combining 4 μl of the annealed oligos with 5 nmol vector backbone (digested with AscI and SbfI, RM396 [SEQ ID NO: 1405]), 1 μl NEB T4 DNA ligase (400,000 U / ml), 1 μl 10x NEB T4 DNA ligase buffer, and ddH2O to 10 μl. The ligation solution was incubated at room temperature for 30 minutes. The entire ligation reaction was transformed into E. coli for clone selection, plasmid isolation, and sequence verification according to known techniques.
[0100] The resulting oligonucleotide has the 5' to 3' nucleotide sequence of SEQ ID NO:930 and is identified as RM409.
[0101] Table 3: Oligo sequences for generating RM409 silk repeat domain (with flanking sequences for cloning) (SEQ ID NO: 930) TIFF2024155944000022.tif145169
[0102] Synthesis of RM410 sequence: Oligos RM2999-RM3014 (SEQ ID NOs: 1492-1507) in Table 4 were combined into a single mixture at a concentration of 100 μM of each oligo. These oligos were phosphorylated in a phosphorylation reaction prepared by combining 1 μl 10x NEB T4 DNA ligase buffer, 1 μl 100 μM pooled oligos, 1 μl NEB T4 polynucleotide kinase (10,000 U / ml), and 7 μl ddH2O and incubating at 37° C. for 1 hour. These oligos were then annealed by mixing 4 μl of the phosphorylation reaction with 16 μl ddH2O, heating the mixture to 95° C. for 5 minutes, and then cooling the mixture to 25° C. at a rate of 0.1° C. / sec. These oligos were then ligated together into the vector by combining 4 μl of the annealed oligos with 5 nmol vector backbone (digested with AscI and SbfI, RM400 [SEQ ID NO: 1406]), 1 μl NEB T4 DNA ligase (400,000 U / ml), 1 μl 10x NEB T4 DNA ligase buffer, and ddH2O to 10 μl. The ligation solution was incubated at room temperature for 30 minutes. The entire ligation reaction was transformed into E. coli for clone selection, plasmid isolation, and sequence verification according to known techniques.
[0103] The resulting oligonucleotide has the 5' to 3' nucleotide sequence of SEQ ID NO:931 and is identified as RM410.
[0104] Table 4: Oligo sequences for generating RM410 silk repeat domain (with flanking sequences for cloning) (SEQ ID NO: 931) TIFF2024155944000023.tif101169
[0105] Assembly and Assay of Argiope bruennichii Masp2, "18B" RM409 (SEQ ID NO: 930) and RM410 (SEQ ID NO: 931) oligonucleotide sequences synthesized according to the methods described above were assembled according to the diagram shown in Figure 6 to generate the RM439 silk nucleotide sequence (e.g., "18B").
[0106] RM409 (SEQ ID NO: 930) and RM410 (SEQ ID NO: 931) in the assembly vector were digested and ligated according to the diagrams shown in FIG. The silk N, R, and C domains, as well as additional elements including the alpha mating factor pre-pro sequence and a 3X FLAG tag, were assembled using the pseudo-scarless 2 antibiotic (2ab) method (Leguia, M., et al., 2ab assembly: a methodology for automatable, high-throughput assembly of standard biological parts, J. Biol. Eng., 7:1 (2013); and Kodumal, SJ, et al., Total synthesis of long DNA sequences: synthesis of a contiguous 32-kb polyketide synthase gene cluster, Proc. Natl. Acad. Sci. USA, 101:44, pg. 15573-15578 (2004)).
[0107] 2ab assembly relies on the use of six assembly vectors that are identical except for the identity and relative positions of the two selectable markers. Each vector is resistant to exactly two of the following: chloramphenicol (CamR), kanamycin (KanR), and ampicillin (AmpR). The order (relative position) of the resistance genes is important, therefore, for purposes of DNA assembly, AmpR / KanR is different from KanR / AmpR. The six assembly vectors are shown in Table 5 and are named based on the two resistance markers in each (C for CamR, K for KanR, and A for AmpR). The six assembly vectors are as follows: The TIFF2024155944000024.tif20146 assembly vector is shown in Table 5. The sequence for the vector includes the sequence of SEQ ID NO: 1399-1410.
[0108] Table 5. Expression and assembly vectors TIFF2024155944000025.tif75163
[0109] 7 shows a single assembly reaction performed with two compatible vectors, AC (RM398 SEQ ID NO:1404) and CK (RM401 SEQ ID NO:1407), one containing the sequence destined for the 5' end of the target composite sequence and one destined for the 3' end of the target composite sequence. The plasmid containing the 5' sequence was independently digested with BbsI, while the plasmid containing the 3' sequence was independently digested with BsaI.
[0110] After inactivation of the enzyme, the two digested plasmids are pooled and ligated. The desired product is present in the AK vector, which is distinct from all input vectors and unwanted by-products. This allows for selection for the desired product after transformation into E. coli.
[0111] The DNA sequence of the cloning site during this process is shown in Figure 8. By choosing the 4 bp overhang created by the Type IIs enzyme to be AGGT, assembly of the DNA fragments will result in a scarless junction in the desired encoded polypeptide, provided that the polypeptide begins with a glycine (encoded by GGT) and ends with a codon that ends in A (all except F, Y, W, C, H, N, M, and D).
[0112] Assembly of RM409 (SEQ ID NO: 930) and RM410 (SEQ ID NO: 931) in the KC and CA assembly vectors, respectively, generated RM411 (SEQ ID NO: 465) in KA, as shown in FIG. 6. The RM411 (SEQ ID NO: 465) sequence was transferred to AC and CA using AscI and SbfI. The RM411 (SEQ ID NO: 465) KA and AC sequences were digested and ligated following the procedure described above to generate RM434 (SEQ ID NO: 466) in KC. Finally, RM434 (SEQ ID NO: 466) in KC was digested and ligated with RM411 (SEQ ID NO: 465) in CA to generate the final silk polypeptide coding sequence RM439 (SEQ ID NO: 467) (aka, "18B").
[0113] Transfer of the "18B" silk polypeptide coding sequence (RM439) into the RM468 expression vector: RM468 (SEQ ID NO: 1401) expression vector contains alpha mating factor sequence and 3X FLAG sequence (SEQ ID NO: 1409). 18B silk polypeptide coding sequence RM439 (SEQ ID NO: 467) was transferred to RM468 (SEQ ID NO: 1401) expression vector by BtgZI restriction enzyme and Gibson reaction kit. RM439 vector was digested with BtgZI, and polynucleotide fragment containing silk sequence was isolated by gel electrophoresis. The expression vector RM468 was amplified by PCR using primers RM3329 and RM3330, excluding unnecessary dummy inserts, using the conditions described in Example 4. The resulting PCR product and isolated silk fragment were combined using Gibson reaction kit according to the manufacturer's instructions. Gibson reaction kits are commercially available (https: / / www.neb.com / products / e2611-gibson-assembly-master-mix) and are described in U.S. Pat. No. 5,436,149 and Gibson, DG et al., Enzymatic assembly of DNA molecules up to several hundred kilobases, Nat. Methods, 6:5, pg. 343-345 (2009).
[0114] The resulting expression vector containing RM439 (SEQ ID NO: 467) was transformed into Pichia (Komagatela) pastoris. The resulting cell clone was cultured according to the following conditions: Cultures were grown in minimal basal salts medium similar to that described in [http: / / tools.invitrogen.com / content / sfs / manuals / pichiaferm_prot.pdf] with 50 g / L glycerol as starting feedstock. Growth was performed in a stirred fermenter vessel controlled at 30C with 1 VVM airflow and 2000 rpm agitation. pH was controlled at 3 by on-demand addition of ammonium hydroxide. Additional glycerol was added as needed based on dissolved oxygen spikes. Growth was continued until dissolved oxygen reached 15% of maximum, at which point cultures were harvested, typically at a cell density of 200-300 OD.
[0115] The culture fluid from the fermenter was decellularized by centrifugation. The supernatant from the Pichia (Komagatela) pastoris culture was collected. Ultrafiltration was used to remove low molecular weight components from the supernatant, removing particles smaller than the block copolymer polypeptide. The filtered culture supernatant was then concentrated up to 50x. The polypeptides in the supernatant were precipitated and analyzed by Western blot. The products are shown in the Western blot in Figure 9. The expected molecular weight of processed 18B is 82 kDa. The product observed in the Western blot in Figure 9 showed a higher MW of approximately 120 kDa. The cause of this discrepancy is unknown, but other silk polypeptides were observed to appear at higher molecular weights than expected.
[0116] The 18B block copolymer polypeptide was purified and processed into a fiber spinning solution. The fiber spinning solution was prepared by dissolving the purified and dried polypeptide in a spinning solvent. The polypeptide is dissolved at 20-30% by weight in the selected solvent. The fiber spinning solution was then extruded through a 150 micron diameter orifice into a coagulation bath containing 90% by volume methanol / 10% by volume water. The fibers were removed from the coagulation and stretched 1-5 times their length and subsequently dried. The resulting fibers are shown in Figure 10.
[0117] Mechanical testing was performed on the 18B block copolymer polypeptide secreted, purified, dissolved, and made into fibers as described above. Fiber mechanical properties were tested in a custom-made tensile tester using standard methods. Test samples were mounted with a gauge length of 5.75 mm and tested at a strain rate of 1%. The resulting force was normalized to the fiber diameter as measured by microscopy. Stress versus strain results are shown in FIG. 11, where each stress-strain curve represents replicate measurements from fibers from a single batch and from a single spinning experiment.
[0118] Example 6 Assembly and assay of 4X repeat R sequences Selected R domains from SEQ ID NOs: 1-1398 that were fully expressed and secreted were ligated to 4x repeat domains using the assembly scheme shown in Figure 12. Ligation was performed as described in Example 4 and shown in Figures 7 and 8. Selected sequences from this ligation of R sequences are shown in Table 6. The sequences for these silk constructs include the full-length silk construct sequences of SEQ ID NOs: 1411-1468. The resulting products, containing the four repeat sequences, the alpha mating factor, and the 3X FLAG domains, were digested with AscI and SbfI to release the desired silk sequences and ligated into the expression vector RM652 (SEQ ID NO: 1400) that had been digested with AscI and SbfI to release the unwanted dummy insert. After clonal isolation from E. coli, the vectors were then transformed into Pichia pastoris. Transformants were plated on YPD agar plates containing 25 μg / ml nourseothricin and incubated at 30° C. for 48 hours. Three clones from each transformation were inoculated into 400 μl of BMGY in a 96-well square well block and incubated at 30° C. for 48 hours with agitation at 1000 rpm. Cells were pelleted by centrifugation and supernatants were collected for analysis of block copolymer polypeptide content by Western blot (FIG. 13). Of the 28 constructs transformed with 4x identical repeat sequences, the majority (18 / 28) had at least one clone with a substantial signal on Western blot, and only one showed no signal at all. Of the two constructs that were each composed of two repeats of two distinct repeat sequences, one showed a strong Western blot signal, while the other showed a moderate Western signal. This confirms that assembling larger block copolymer-expressing polynucleotides from smaller well-expressed polynucleotides generally results in functionally expressed block copolymer polypeptides. Streakiness, multiple bands, and inter-clonal variation are evident on Westerns.Although the specific causes of these variations have not been identified, they are generally consistent with typically observed phenomena including polypeptide degradation, post-translational modifications (e.g., glycosylation), and clonal mutations following genomic integration. Modified and degraded polypeptide products can be incorporated into fibers without adversely affecting the utility of the fibers, depending on the intended use.
[0119] Table 6. Full-length block copolymer silk constructs with α-mating factor, 4X repeat domains, and 3X FLAG domains TIFF2024155944000026.tif149142
[0120] Example 7 Expression of 18B from Bacillus subtilis The E. coli / B. subtilis shuttle and expression plasmid is first constructed. The polynucleotide encoding 18B is transferred to the plasmid pBE-S (Takara Bio Inc.) using the Gibson reaction. In the PCR reaction, the primers TIFF2024155944000027.tif35160 is used to amplify plasmid pBE-S (SEQ ID NO: 1512). The reaction mixture consists of 1 μl of 10 μM BES-F, 1 μl of 10 μM BES-R, 0.5 μg of pBE-S DNA (1 μl volume), 22 μl of deionized H2O, and 25 μl of Phusion High-Fidelity PCR Master Mix (NEB catalog M0531S). The mixture is thermocycled according to the following program: 1) Denature at 95℃ for 5 minutes 2) Denature at 95°C for 30 seconds. 3) Anneal at 55°C for 30 seconds. 4) Extend at 72°C for 6 minutes 5) Repeat steps 2-4 for 29 additional cycles. 6) Final extension at 72°C for 5 minutes.
[0121] The product is subjected to gel electrophoresis using Zymoclean Gel DNA Recovery Kit (Zymo Research) according to the manufacturer's instructions, and the approximately 6000 bp product is isolated and then extracted. The polynucleotide encoding 18B is isolated by digestion of 18B in the KA assembly vector with the restriction enzyme BtgZI, followed by gel electrophoresis, fragment isolation, and gel extraction. The pBE-S and 18B fragments are ligated together using Gibson Assembly Master Mix (New England Biolabs) according to the manufacturer's instructions, and the resulting plasmid is transformed into E. coli using standard techniques for subsequent clone isolation, DNA amplification, and DNA purification. The resulting plasmid, pBE-S-18B (SEQ ID NO: 1513), is then diversified by insertion of various signal peptides according to the manufacturer's instructions ("SP DNA mixture"). The mixture of pBE-S-18B plasmids containing different secretion signal peptides is then transformed into B. subtilis strain RIK1285 according to the manufacturer's instructions. The 96 resulting colonies are incubated in TY medium (10 g / L tryptone, 5 g / L yeast extract, 5 g / L NaCl) for 48 hours, at which point the cells are pelleted and the supernatants are analyzed by Western blot for expression of the 18B polypeptide.
[0122] Example 8 Expression of 18B from Chlamydomonas reinhardtii An E. coli vector carrying the excisable C. reinhardtii expression cassette pChlamy (SEQ ID NO: 1514) is first constructed using commercial DNA synthesis and standard techniques. The cassette is described in detail in Rasala, BA, Robust expression and secretion of Xylanase1 in Chlamydomonas reinhardtii by fusion to a selection gene and processing with the FMDV 2A peptide, PLoS One, 7:8 (2012). A polypeptide encoding 18B, a 3xFLAG tag, and a stop codon is back-translated using the codon selection of C. reinhardtii (available, for example, at http: / / www.kazusa.or.jp / codon / cgi-bin / showcodon.cgi?species=3055) and synthesized using commercial synthesis. During the course of synthesis, flanking BbsI sites are included to allow release of the 18B-3xFLAG polynucleotide. The polynucleotide resulting from PCR amplification of the pChlamy plasmid with primers designed to generate a linear fragment containing the entire plasmid sequence except for 5'-ATGTTTTAA-3' and additionally containing 40 bp of homology to the 18B-3xFLAG coding sequence at each end is ligated using a Gibson reaction with the 18B-3xFLAG polynucleotide liberated by digestion with BbsI and transformed into E. coli for clone selection, DNA amplification, and plasmid isolation. The resulting plasmid is digested with BsaI to release the 18B expression cassette, which is isolated by gel purification. The digested fragment is electroporated into strain cc3395, which is then selected with 15 μg / ml Zeocin. Several clones are grown in liquid culture, the cells are pelleted by centrifugation, and the supernatant is analyzed for protein expression by Western blot.
[0123] Example 9 Additional silk and silk-like sequences Additional silk and silk-like sequences and partial sequences were obtained from the NCBI sequence database by searching for the term "silk" while excluding "spidroin", "bombyx" and "latrodectus". A subset of the obtained nucleotide sequences was translated into amino acid sequences and then screened to remove repeated sequences. Short sequences, generally less than 200-500 amino acids in length, were removed. Furthermore, primary sequences were obtained from public databases to select polypeptides known to form structural elements. In addition to the sequences described in Example 1, the amino acid sequences so obtained were used to search for additional silk and silk-like sequences by homology. The obtained silk and silk-like sequences were screened and then partitioned into repetitive and non-repetitive regions.
[0124] Repeated polypeptide sequences (repeat (R) sequences) were selected from each silk sequence, including SEQ ID NOs: 2157-2690 (SEQ ID NOs: 2157-2334 are nucleotide sequences, SEQ ID NOs: 2335-2512 are nucleotide sequences with flanking sequences for cloning, and SEQ ID NOs: 2513-2690 are amino acid sequences). Parts of the R sequences were modified, for example by adding a serine to the C-terminus, so that the sequence does not end with an F, Y, W, C, H, N, M, or D amino acid. This allows for incorporation into the vector system described above. Incomplete blocks may also be modified by incorporation of a segment from a homologous sequence from another block.
[0125] Non-repetitive N-terminal domain sequences (N-sequences) and C-terminal domain sequences (C-sequences) were also selected from several silk and silk-like sequences (SEQ ID NOs: 2157-2690). The N-terminal domain sequences were altered by removal of the leading signal sequence and, if not already present, by addition of an N-terminal glycine residue. In some cases, the N and / or C domains were not separated from the R sequence before further processing. The R, N and C amino acid sequences were back-translated into nucleotide sequences as described in Example 2. The resulting nucleotide sequences were flanked by the following sequences during synthesis to allow cloning: TIFF2024155944000028.tif5139 where "silk" is a polynucleotide sequence selected in accordance with the teachings above.
[0126] The resulting linear DNA was digested with BbsI and ligated into vector RM747 (SEQ ID NO: 2696) that had been digested with BsmBI to release a dummy insert. The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods. The resulting plasmid was digested with BsaI and BbsI, and the fragment encoding the silk or silk-like polypeptide was isolated by gel electrophoresis, fragment excision, and gel extraction. The fragment was subsequently ligated into expression vector RM1007 (SEQ ID NO: 2707) that had been digested with BsmBI and treated with calf intestinal alkaline phosphatase. The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods.
[0127] Expression vectors containing the R, N, and / or C sequences were transformed into Pichia (Komagatela) pastoris (strain RMs71 described in Example 3) using the PEG method (Cregg, JM et al., DNA-mediated transformation, Methods Mol. Biol., 389, pg. 27-42 (2007)). The expression vector consisted of the targeting region and promoter (pGAP), a dominant resistance marker (conferring resistance to nat-neurseothricin), a secretion signal (alpha mating factor leader and prosequence), a C-terminal 3xFLAG epitope, and a terminator (pAOX1 pA signal).
[0128] Transformants were plated onto Yeast Extract Peptone Dextrose Medium (YPD) agar plates containing 25 μg / ml nourseothricin and incubated for 48 hours at 30° C. Two clones from each transformation were inoculated into 400 μl of Buffered Glycerol-complex Medium (BMGY) in a 96-well square well block and incubated for 48 hours at 30° C. with agitation at 1000 rpm. Cells were pelleted by centrifugation and supernatants were collected for analysis of block copolymer polypeptide content by Western blot analysis of the 3×FLAG epitope.
[0129] Successful polypeptide expression and secretion was judged by Western blot. Each Western lane was scored as 1: no band, 2: moderate band, or 3: strong band. The higher of the two scores for each clone was recorded. Representative Western blot data is shown in FIG. 14. A complete list of all R, N, and C sequences tested is shown in Table 7 along with the Western blot results. Silk and silk-like block copolymer polypeptides from multiple species, encompassing a variety of species and a variety of polypeptide structures, were successfully expressed.
[0130] Although a number of embodiments of the invention have been described, it will be understood that various modifications can be made without departing from the spirit and scope of the invention.
[0131] Table 7: Additional silk polypeptide sequences TIFF2024155944000029.tif65170TIFF2024155944000030.tif206170TIFF2024155944000031.tif240170TIFF2024155944000032.tif249170 TIFF2024155944000033.tif245170TIFF2024155944000034.tif243170TIFF2024155944000035.tif236170TIFF2024155944000036.tif213170
[0132] Example 10 Circular permutants of the Argiope bruennichii MaSp2 polypeptide The six repeat blocks (block copolymers) from Argiope bruenichii MaSp2 identified in Example 5 were circularly permuted by approximately 90 degrees (by moving approximately 1.5 blocks from the end of the six blocks to the beginning) and then split into two R sequences, RM2398 (SEQ ID NO: 2708) and RM2399 (SEQ ID NO: 2709), each consisting of approximately three blocks. These three-block sequences were subsequently used to generate six-block sequences rotated approximately 90 and approximately 270 degrees from the original six-block sequence, and the existing three-block sequences (RM409 and RM410) were used to generate six-block sequences rotated approximately 180 degrees. Each six-block sequence was then assembled into an 18-block sequence. The assembly process and rotated sequences are shown in FIG. 15.
[0133] To generate RM2398 and RM2399, either primer Plasmid RM439 (SEQ ID NO: 467) was amplified by PCR using TIFF2024155944000037.tif49164. Each reaction consisted of 12.5 μL 2x KOD Extreme Buffer, 0.25 μl KOD Extreme Hot Start Polymerase, 0.5 μl 10 μM Fwd oligo, 0.5 μl 10 μM Rev oligo, 5 ng template DNA (RM439), 0.5 μl of 10 mM dNTPs, and ddH2O added to a final volume of 25 μl. Each reaction was then thermocycled according to the following program: 1. Denature at 94°C for 5 minutes 2. Denature at 94°C for 30 seconds 3. Anneal at 55°C for 30 seconds. 4. Extend at 72°C for 60 seconds. 5. Repeat steps 2-4 for 29 additional cycles. 6. Final extension at 72°C for 5 min
[0134] The resulting linear DNA was digested with BsaI and ligated into BsmBI-digested assembly vectors RM2086 (SEQ ID NO: 2693) and RM2089 (SEQ ID NO: 2695). The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods. Using the 2ab assembly process described in Example 5 (with minor modifications to the assembly vector to shift the BtgZI cleavage site further away from the silk sequence), the 3-block fragment was assembled into two different 6-block fragments, one with RM2398 followed by (proceeding) RM2399 (producing RM2452 - SEQ ID NO: 2710) and one with RM2399 followed by RM2398 (producing RM2454 - SEQ ID NO: 2712). In addition, RM409 (SEQ ID NO 463) and RM410 (SEQ ID NO 464) were digested from assembly vector RM396 with BbsI and BsaI and ligated into vector RM2105 (SEQ ID NO: 2691) that had been digested with BbsI and BsaI and treated with calf intestinal alkaline phosphatase. The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods. The resulting plasmid was then digested with AscI and SbfI, and the silk-encoding fragment was isolated by gel electrophoresis, fragment excision, and gel extraction. The fragment was then ligated into assembly vectors RM2086 and RM2089 that had been digested with AscI and SbfI. The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods. 2ab assembly was used to generate a 6-block fragment consisting of RM410 followed by RM409 (producing RM2456 - SEQ ID NO: 2711). RM2452, RM2454, and RM2456 were digested from assembly vector RM2081 (SEQ ID NO: 2692) with AscI and SbfI and ligated into assembly vectors RM2088 and RM2089 that had been digested with AscI and SbfI.The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods. Using 2ab assembly, an 18-block sequence was generated from each of the three 6-block fragments, resulting in sequences RM2462 (SEQ ID NO: 2713), RM2464 (SEQ ID NO: 2715), and RM2466 (SEQ ID NO: 2714). Each of the 6-block and 18-block sequences was then digested from the assembly vector with BsaI and BbsI, and the silk-encoding fragments were isolated by gel electrophoresis, fragment excision, and gel extraction. The fragments were subsequently ligated into the expression vector RM1007 (SEQ ID NO: 2707) that had been digested with BsmBI and treated with calf intestinal alkaline phosphatase. The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods. The resulting plasmid was linearized with BsaI and used to transform into Pichia (Komagatela) pastoris (strain RMs71 described in Example 3) using the PEG method (Cregg, JM et al., DNA-mediated transformation, Methods Mol. Biol., 389, pg. 27-42 (2007)). Transformants were plated onto Yeast Extract Peptone Dextrose Medium (YPD) agar plates containing 25 μg / ml nourseothricin and incubated at 30° C. for 48 hours. Two clones from each transformation were inoculated into 400 μl of buffered glycerol complex medium (BMGY) in a 96-well square well block and incubated at 30° C. for 48 hours with agitation at 1000 rpm. Cells were pelleted by centrifugation and supernatants were collected for analysis of silk polypeptide content by Western blot analysis of the 3xFLAG epitope. Western blot data for representative clones of each polypeptide are shown in FIG. 16. The expression and secretion of each of the circularly permuted polypeptides appears to be comparable to its unpermuted counterpart.This suggests that any number of start positions can be chosen to specify blocks in a repeated silk or silk-like polypeptide without affecting the expression or secretion of the polypeptides composed of those blocks.
[0135] Example 11 Altering expression of Argiope bruennichii MaSp2 polynucleotide by controlling copy number and promoter strength The degree of transcription of an exogenously introduced polynucleotide is known to affect the amount of polypeptide produced (see, e.g., Liu, H., et al., Direct evaluation of the effect of gene dosage on secretion of protein from yeast Pichia pastoris by expressing EGFP, J. Microbiol. Biotechnol., 24:2, pg. 144-151 (2014); and Hohenblum, H., et al., Effects of gene dosage, promoters, and substrates on unfolded protein stress of recombinant Pichia pastoris, Biotechnol. Bioeng., 85:4, pg. 367-375 (2004)).In Pichia (Komagatela) pastoris, the level of transcription is generally controlled by increasing the copy number of the polynucleotide integrated into the host genome or by selecting an appropriate promoter to drive transcription (e.g., Hartner, FS, et al., Promoter library designed for fine-tuned gene expression in Pichia pastoris, Nucleic Acids Res., 36:12 (2008); Zhang, AL, et al., Recent advances on the GAP promoter derived expression system of Pichia pastoris, Mol. Biol. Rep., 36:6, pg. 1611-1619 (2009); Ruth, C., et al., Variable production windows for porcine trypsinogen employing synthetic inducible promoter variants in Pichia pastoris, Syst. Synth. Biol., 4:3, pg. 181-191 (2010); Stadlmayr, G., et al., (see, e.g., et al., Identification and characterisation of novel Pichia pastoris promoters for heterologous protein production, J. Biotechnol., 150:4, pg. 519-529 (2010)).A relatively recent addition to the set of promoters used for heterologous protein expression is pGCW14 (Liang, S., Identification and characterization of P GCW14: a novel, strong constitutive promoter of Pichia pastoris, Biotechnol. Lett. 35:11, pg. 1865-1871 (2013)), which has been reported to be 5-10 times stronger than pGAP. To confirm that expression and secretion of silk and silk-like polypeptides can also be influenced by copy number, strains containing 1, 3, or 4 copies of pGAP driving expression of 18B (described in Example 5) and 1, 2, 3, or 4 copies of pGCW14 driving expression of 18B were generated and tested. The strains are listed in Table 8.
[0136] Table 8. Strains with multiple polynucleotide sequences or different promoters TIFF2024155944000038.tif67154
[0137] A polynucleotide sequence encoding α-mating factor + 18B + 3xFLAG tag was digested with the restriction enzymes AscI and SbfI from the plasmid (RM439, SEQ ID NO: 467 cloned into, RM468, SEQ ID NO: 1401) described in Example 5. The fragment encoding α-mating factor + 18B + 3xFLAG tag was isolated by gel electrophoresis, fragment excision, and gel extraction. The resulting linear DNA was ligated into AscI and SbfI digested expression vectors RM630 (SEQ ID NO: 2697), RM631 (SEQ ID NO: 2698), RM632 (SEQ ID NO: 2699), RM633 (SEQ ID NO: 2700), RM812 (SEQ ID NO: 2701), RM837 (SEQ ID NO: 2702), RM814 (SEQ ID NO: 2703), and RM815 (SEQ ID NO: 2704). Key attributes of the expression vectors are summarized in Table 9, and sequences include SEQ ID NOs: 2691-2707. The ligated material was transformed into E. coli for clone isolation, DNA amplification, and sequence verification using standard methods.
[0138] Table 9. Additional vectors TIFF2024155944000039.tif167161
[0139] The polynucleotide encoding 18B in the expression vector RM630 was linearized with BsaI and transformed into Pichia (Komagatela) pastoris (strain GS115 - NRRL Y15851) using the PEG method (Cregg, JM et al., DNA-mediated transformation, Methods Mol. Biol., 389, pg. 27-42 (2007)). Transformants were plated on minimal dextrose (MD) agar plates (without added amino acids) and incubated at 30°C for 48 hours. This generated strain RMs126, 1x pGAP 18B.
[0140] RMs126 was then co-transformed with the polynucleotide encoding 18B in expression vectors RM632 and RM633 (linearized with BsaI) using electroporation (Wu., S., and Letchworth, GJ, High efficiency transformation by electroporation of Pichia pastoris pretreated with lithium acetate and dithiothreitol, Biotechniques, 36:1, pg. 152-154 (2004)). Transformants were plated onto yeast extract peptone dextrose medium (YPD) agar plates containing 25 μg / ml nourseothricin and 100 μg / ml hygromycin B and incubated at 30° C. for 48 hours. This generated strain RMs127, 3x pGAP 18B.
[0141] RMs127 was then transformed with the polynucleotide encoding 18B in expression vector RM631 (linearized with BsaI) using the PEG method. Transformants were plated onto yeast extract peptone dextrose medium (YPD) agar plates containing 300 μg / ml G418 and incubated at 30° C. for 48 hours, generating strain RMs134, 4x pGAP 18B.
[0142] To generate strains RMs133, RMs138, RMs143, and RMs152 (1x, 2x, 3x, and 4x p754 18B, respectively), strain GS115 (NRRL Y15851) was transformed sequentially with polynucleotides encoding 18B in expression vectors RM812, RM814, RM815, and RM837 (after linearization with BsaI) using the PEG method.
[0143] A clone of each strain was inoculated into 400 μl of buffered glycerol complex medium (BMGY) in a 96-well square well block and incubated at 30° C. for 48 hours with agitation at 1000 rpm. Cells were pelleted by centrifugation and supernatants were collected for analysis of block copolymer polypeptide content by Western blot analysis of the 3×FLAG epitope. Western blot data for representative clones of each polypeptide is shown in FIG. 16. The increase in band intensity suggests that higher transcription resulted in the expression and secretion of additional block copolymer polypeptides, confirming that the strategy of increasing transcription works for block copolymers based on silk and silk-like polypeptide repeat units.
[0144] Example 12 Comparison of expression and secretion of single R domains with homopolymers of R domains Additional selected R domains from fully expressed and secreted SEQ ID NOs: 1-1398 were linked to the 4-6x repeat domains using 2ab assembly (described in Example 5). In addition, 12B sequences were linked to 18B sequences (from Example 5) using 2ab assembly to obtain 30B sequences. The resulting products were transferred to an expression vector such that each silk sequence was flanked by an α-junction domain at the 5' end and a 3xFLAG domain at the 3' end, and driven by the pGAP promoter. The sequences generated are listed in Table 10 and include SEQ ID NOs: 2734-2748.
[0145] Table 10. Additional full-length block copolymer constructs with α-mating factor, multiple repeat domains, and 3X FLAG domains TIFF2024155944000040.tif104170
[0146] The block copolymer expression vectors were then transformed into Pichia (Komagatela) pastoris (strain RMs71 described in Example 3) using the PEG method (Cregg, JM et al., DNA-mediated transformation, Methods Mol. Biol., 389, pg. 27-42 (2007)). Transformants were plated onto YPD agar plates containing 25 μg / ml nourseothricin and incubated at 30° C. for 48 hours. Three clones from each transformation were taken up in 400 μl of BMGY in a 96-well square well block and incubated at 30° C. for 48 hours with agitation at 1000 rpm. Cells were pelleted by centrifugation and supernatants were collected for analysis of silk polypeptide content by Western blot. Representative clones for each block copolymer construct, as well as the 1× R domain equivalent and 4× R domain constructs from Example 6, are shown in FIG. 16. As observed in Example 6, streaking and multiple bands are evident on the Western. Although the specific causes of these variations have not been identified, they are generally consistent with typically observed phenomena, including polypeptide degradation and post-translational modifications (e.g., glycosylation). Furthermore, the band intensities of 4-6x R domain polypeptides appear to be weaker than the corresponding 1x R domain constructs. This is also evident in the 6B, 12B, 18B, and 30B series of Argiope bruennichii MaSp2 polypeptides. This suggests that longer block copolymers containing silk repeat sequences are generally less expressed and secreted than shorter block copolymer sequences containing the same or different repeat sequences.
[0147] Example 13 Measurement of productivity of strains expressing and secreting silk Table 11 lists the volumetric and specific productivities of strains expressing the polypeptides described in Example 10, Example 11, and Example 12.
[0148] Table 11. Productivity of strains producing silk polypeptides TIFF2024155944000041.tif238152TIFF2024155944000042.tif157152
[0149] To measure productivity, three clones of each strain were inoculated into 400 μl of buffered glycerol complex medium (BMGY) in a 96-well square well block and incubated at 30° C. for 48 hours with agitation at 1000 rpm. After 48 hours of incubation, 4 μl of each culture was used to inoculate 400 μl of fresh BMGY in a 96-well square well block, which was then incubated at 30° C. for 24 hours with agitation at 1000 rpm. The cells were then pelleted by centrifugation, the supernatant was removed, and the cells were resuspended in 400 μl of fresh BMGY. The cells were pelleted again by centrifugation, the supernatant was removed, and the cells were resuspended in 800 μl of fresh BMGY. From the 800 μl, 400 μl was aliquoted into a 96-well square well block, which was then incubated at 30° C. for 2 hours with agitation at 1000 rpm. After 2 hours, the OD600 of the cultures was recorded, the cells were pelleted by centrifugation, and the supernatants were collected for further analysis. The concentration of block copolymer polypeptide in each supernatant was determined by direct enzyme-linked immunosorbent assay (ELISA) analysis to quantify the 3xFLAG epitope.
[0150] The relative productivity of each strain confirms the qualitative observations made based on the Western blot data. Circularly permuted polypeptides are expressed at similar levels to unpermuted silk, stronger promoters or more copies result in higher block copolymer expression and secretion, and longer block copolymer polypeptides containing silk repeat sequences are generally less expressed than shorter block copolymers containing the same or different repeat sequences. Interestingly, grams of 12B (55.9 kDa) produced exceeded grams of 6B (29.5 kDa) produced, suggesting that factors leading to reduced expression of larger block copolymers containing silk repeat sequences may not be prevalent until expression of block copolymers closer in size to 18B (82.2 kDa). Importantly, most of the block copolymer polypeptides have relatively high specific productivity (>0.1 mg silk / g Dry Cell Weight (DCW) / hr, in some embodiments, the productivity is greater than 2 mg silk / g DCW / hr, in further embodiments, the productivity is greater than 5 mg silk / g DCW / hr) even before any optimization of the polypeptide transcription level. Further transcription improved the productivity of 18B by approximately 5-fold, to 20 (nearly 21) mg polypeptide / g DCW / hr.
[0151] Example 14 Measurement of mechanical properties of silk fibers The block copolymer polypeptide produced in Example 5 was spun into fibers and tested for various mechanical properties. A fiber spinning solution was first prepared by dissolving the purified and dried block copolymer polypeptide in a formic acid-based spinning solvent using standard techniques. The spin dope was incubated at 35° C. on a rotating shaker with occasional mixing for three days. After three days, the spin dope was centrifuged at 16000 rcf for 60 minutes and allowed to equilibrate to room temperature for at least two hours before spinning.
[0152] The spin dope was extruded through a 50-200 μm diameter orifice into a standard alcohol-based coagulation bath. The fibers were pulled out of the coagulation bath under tension and stretched 1-5 times their length, followed by drying. At least five fibers were randomly selected from at least 10 meters of spun fiber. These fibers were tested for tensile mechanical properties using an instrument containing a linear actuator and a calibrated load cell. The fibers were pulled to failure at 1% strain. Fiber diameter was measured by optical microscopy at 20x magnification using image processing software. The average maximum stress ranged from 54 to 310 MPa. The average yield stress ranged from 24 to 172 MPa. The average maximum strain ranged from 2 to 200%. The average initial modulus ranged from 1617 to 5820 MPa. The effect of draw ratio is shown in Table 12 and Figure 17. Additionally, the average toughness of the three fibers was measured at 0.5 MJ m -3 (standard deviation 0.2), 20 MJ m -3 (standard deviation 0.9), and 59.2 MJ m -3 (standard deviation 8.9).
[0153] Table 12. Effect of stretch ratio TIFF2024155944000043.tif61164
[0154] Fiber diameter was determined as the average value of at least 4-8 fibers randomly selected from at least 10 m of spun fiber. For each fiber, six measurements were taken over a span of 0.57 cm. Diameters ranged from 4.48 to 12.7 μm. Fiber diameters were consistent within the same sample. Samples spanned a range of average diameters: 10.3 μm (standard deviation 0.4 μm), 13.47 μm (standard deviation 0.36 μm), 12.05 μm (standard deviation 0.67), 14.69 μm (standard deviation 0.76 μm), and 9.85 μm (standard deviation 0.38 μm).
[0155] One particularly useful fiber spun from the block copolymer material produced from the optimized recovery and separation protocol had a maximum ultimate tensile strength of 310 MPa, an average diameter of 4.9 μm (standard deviation 0.8), and a maximum strain of 20%. Fiber tensile test results are shown in FIG.
[0156] The fibers were allowed to dry at room temperature overnight. -1 Resolution: 400 cm -1 From 4000 cm -1 FTIR spectra were collected using a Diamond ATR module up to 1000 nm (Figure 19). -1 ~1700 cm -1 ) was baselined and curve-fitted with a Gaussian distribution at 5-6 positions determined by the peak position from the second derivative of the original curve. Approximately 1620 cm divided by the total area of the amide I region -1 and about 1690 cm -1 The β-sheet content was determined as the area under a Gaussian distribution at 1.5 Torr. Annealed and untreated fibers were tested. For annealing, the fibers were incubated in a humid vacuum chamber at 1.5 Torr for at least 6 hours. The untreated fibers were found to contain 31% β-sheet content and the annealed fibers were found to contain 50% β-sheet content.
[0157] Fiber cross-sections were examined by freeze fracturing using liquid nitrogen. Samples were sputter coated with platinum / palladium and imaged using a Hitachi TM-1000 at 5 kV accelerating voltage. Figure 20 shows that the fibers have smooth surfaces, circular cross-sections, and are solid and void-free. In some embodiments,
[0158] Example 15 Optimal fiber production An R domain of a MaSp2-like silk is selected from those listed in Tables 13a and 13b, and the R domain is linked to a 4x repeat domain flanked by an alpha mating factor at the 5' end and a 3X FLAG at the 3' end using the assembly scheme shown in Figure 12. Linking is performed as described in Example 4 and shown in Figures 7 and 8. The resulting polynucleotide sequences and corresponding polypeptide sequences are listed in Tables 13a and 13b.
[0159] For the sequences in Tables 13a and 13b: (1) the proline content is in the range of 11.35-15.74% (the percentages in Tables 13a and 13b refer to the number of amino acid residues of the stated content, in this case prolines, relative to the total number of amino acid residues in the corresponding polypeptide sequence). The proline content of similar R domains can also be in the range of 13-15%, 11-16%, 9-20%, or 3-24%; (2) the alanine content is in the range of 16.09-30.51%. The alanine content of similar R domains can also be in the range of 15-20%, 16-31%, 12-40%, or 8-49%; (3) the glycine content is in the range of 29.66-42.15%. The glycine content of similar R domains may also range from 38 to 43%, 29 to 43%, 25 to 50%, or 21 to 57%; (4) the glycine and alanine content ranges from 54.17 to 68.59%. The glycine and alanine content of similar R domains may also range from 54 to 69%, 48 to 75%, or 42 to 81%; (5) the β-turn content ranges from 18.22 to 32.16%. The β-turn content is calculated using the SOPMA method from Geourjon, C., and Deleage, G., SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments, Comput. Appl. Biosci., 11:6, pg. 681-684 (1995). The SOPMA method is applied with the following parameters: window width-10; similarity threshold-10; number of states-4. The β-turn content of similar R domains can also range from 25-30%, 18-33%, 15-37%, or 12-41%; (6) the polyalanine content ranges from 12.64-28.85%. A motif is considered a polyalanine motif if it contains at least four consecutive alanine residues. The polyalanine content of similar R domains can also range from 12-29%, 9-35%, or 6-41%; (7) the GPG motif content ranges from 22.95-46.67%.The GPG motif content of similar R domains may also range from 30-45%, 22-47%, 18-55%, or 14-63%; (8) the GPG and polyalanine content ranges from 42.21-73.33%. The GPG and polyalanine content of similar R domains may also range from 25-50%, 20-60%, or 15-70%. Other silk types exhibit different ranges of amino acid content and other properties. Figure 21 shows the range of glycine, alanine, and proline content for various silk types of silk polypeptide sequences disclosed herein. Figure 21 shows the percentage of glycine, alanine, or proline amino acid residues relative to the total number of residues in the polypeptide sequence.
[0160] The resulting product of ligation, containing the four repeat sequences, the α mating factor, and the 3X FLAG domain, is digested with AscI and SbfI to release the desired silk sequence and ligated into AscI- and SbfI-digested expression vectors RM812 (SEQ ID NO: 2701), RM837 (SEQ ID NO: 2702), RM814 (SEQ ID NO: 2703), and RM815 (SEQ ID NO: 2704) (key attributes of the expression vectors are summarized in Table 9). A strain containing four copies of the silk polynucleotide under the transcriptional control of pGCW14 is generated by sequentially transforming the resulting expression vectors (after linearizing them with BsaI) into Pichia (Komagatela) pastoris strain GS115 (NRRL Y15851) using the PEG method. Similar quasi-repeat domains can range from 500-5000, 119-1575, 300-1200, 500-1000, or 900-950 amino acids in length. The entire block copolymer can range from 40-400, 12.2-132, 50-200, or 70-100 kDa.
[0161] Table 13a. Characteristics of selected R domains TIFF2024155944000044.tif186151
[0162] Table 13b. Characteristics of selected R domains TIFF2024155944000045.tif185169
[0163] The resulting clone of the strain is cultivated according to the following conditions: Cultures are grown in minimal basal salts medium similar to that described in [http: / / tools.invitrogen.com / content / sfs / manuals / pichiaferm_prot.pdf] with 50 g / L glycerol as starting feedstock. Growth is performed in a stirred fermenter vessel controlled at 30C with 1 VVM airflow and 2000 rpm agitation. pH is controlled at 3 by on-demand addition of ammonium hydroxide. Additional glycerol is added as needed based on dissolved oxygen spikes. Growth is continued until dissolved oxygen reaches 15% of maximum, at which point cultures are harvested, typically at a cell density of 200-300 OD.
[0164] The culture fluid from the fermenter is decellularized by centrifugation. The supernatant from the Pichia (Komagatela) pastoris culture is collected. Ultrafiltration is used to remove low molecular weight components from the supernatant, removing particles smaller than the block copolymer polypeptide. The filtered culture supernatant is then concentrated up to 50x.
[0165] A fiber spinning solution is prepared by dissolving the purified and dried block copolymer polypeptide in a formic acid-based spinning solvent. The spin dope is incubated at 35°C on a rotating shaker with occasional mixing for 3 days. After 3 days, the spin dope is centrifuged at 16000 rcf for 60 minutes and allowed to equilibrate to room temperature for at least 2 hours before spinning. The spin dope is extruded through a 150 μm diameter orifice into a standard alcohol-based coagulation bath. The fibers are pulled out of the coagulation bath under tension and stretched 1-5 times their length, followed by drying as tight hanks.
[0166] At least five fibres are randomly selected from at least 10 metres of spun fibre. The fibres are tested for tensile mechanical properties using custom-built equipment including a linear actuator and calibrated load cell. The fibres are mounted with a gauge length of 5.75 mm and pulled at a 1% strain rate until failure. The ultimate tensile strength of the fibres is measured to be 50-500 MPa. Depending on which fibre is selected, the yield stress is measured to be 24-172 MPa or 150-172 MPa, the ultimate tensile strength (maximum stress) is measured to be 54-310 MPa or 150-310 MPa, the breaking strain is measured to be 2-200% or 180-200%, the initial modulus is measured to be 1617-5820 MPa or 5500-5820 MPa and the toughness value is measured to be at least 0.5 MJ / m 3 , at least 3.1 MJ / m 3 , or at least 59.2 MJ / m 3 It is measured to be.
[0167] The resulting force is normalized to fiber diameter as measured by optical microscopy. Fiber diameter is measured by optical microscopy at 20x magnification using image processing software. Fiber diameter is determined as the average value of at least 4-8 fibers randomly selected from at least 10 m of spun fiber. For each fiber, six measurements are taken over a 5.75 mm span. Depending on which fiber is selected, fiber diameters are measured to be 4-100 μm, 4.48-12.7 μm, or 4-5 μm.
[0168] To test the β-sheet crystalline content of the fibers, the fibers are dried overnight at room temperature. -1 Resolution: 400 cm -1 From 4000 cm -1 FTIR spectra are collected using a Diamond ATR module up to the amide I region (1600 cm -1 ~1700 cm -1) and curve fit with a Gaussian distribution at 5-6 positions determined by the peak position from the second derivative of the original curve. Approximately 1620 cm divided by the total area of the amide I region. -1 and about 1690 cm -1 The β-sheet content is determined as the area under a Gaussian distribution at 1.5 Torr. To induce β-sheet crystallization, the fibers are incubated in a humid vacuum chamber at 1.5 Torr for at least 6 hours. Fiber surface morphology and cross-sections (obtained by freeze-fracturing with liquid nitrogen) are analyzed by scanning electron microscopy. Samples are sputter-coated with platinum / palladium and imaged with a Hitachi TM-1000 at 5 kV accelerating voltage.
[0169] Although a number of embodiments of the invention have been described, it will be understood that various modifications can be made without departing from the spirit and scope of the invention.
Claims
[Claim 1] The invention described herein.
